[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 284
1. Sengul D, Sengul I, Astarci MH, Ustun H, Mocan G: Differential diagnosis of basal cell carcinoma and benign tumors of cutaneous appendages originating from hair follicles by using CD34. Asian Pac J Cancer Prev; 2010;11(6):1615-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of basal cell carcinoma and benign tumors of cutaneous appendages originating from hair follicles by using CD34.
  • BACKGROUND AND AIMS: Differential diagnosis of the group of benign trichoblastomas, trichofolliculomas, trichoadenomas and trichoepitheliomas, and basal cell carcinomas (BCCs) is troublesome for the clinician as well as the pathologist, especially when only small biopsy specimens are available.
  • METHODS: Thirty benign tumors of cutaneous appendages originating from hair follicles (BTCOHF) and 30 BCCs were retrieved from our archives and immunohistochemically stained.
  • [MeSH-major] Antigens, CD34 / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Skin Appendage / diagnosis. Hair Diseases / diagnosis. Hair Follicle / pathology. Neoplasms, Basal Cell / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21338206.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor
  •  go-up   go-down


2. Sengul D, Sengul I, Astarci MH, Ustun H, Mocan G: CD10 for the distinct differential diagnosis of basal cell carcinoma and benign tumours of cutaneous appendages originating from hair follicle. Pol J Pathol; 2010;61(3):140-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10 for the distinct differential diagnosis of basal cell carcinoma and benign tumours of cutaneous appendages originating from hair follicle.
  • AIMS: Differential diagnosis between the group of trichoadenoma, trichofolliculoma, trichoepithelioma, trichoblastoma and basal cell carcinoma has been creating some difficulties for the pathologist and the clinicians, particularly in the presence of small specimens.
  • MATERIAL AND METHODS: A total of 30 cases of benign tumours of cutaneous appendages originating from the hair follicle and 30 cases of basal cell carcinoma were retrieved from the archives deposited from 2004 to 2008.
  • The stromal CD10 immunopositivity of benign tumours of cutaneous appendages originating from the hair follicle was stronger than the other (p = 0.003) regarding both the numerical and the degree of expression.
  • However, peripheral CD10 of basal cell carcinoma was stronger than the other for [1+] immunopositivity (p = 0.03).
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Skin Appendage / diagnosis. Hair Follicle / pathology. Neprilysin / metabolism. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21225496.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


3. Farah-Klibi F, Ferchiou M, Kourda J, El Amine O, Ferjaoui M, Ben Jilani S, Zermani R: [Parotid basal cell adenoma of membranous type]. Tunis Med; 2009 Feb;87(2):149-51
MedlinePlus Health Information. consumer health - Sarcoidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Parotid basal cell adenoma of membranous type].
  • [Transliterated title] Adenome a cellules basales de type membraneux de la parotide.
  • INTRODUCTION: Basal cell adenoma (BCA) is a rare benign neoplasm characterized by the basaloid appearance of the tumour cells and the lack of myxo-chondroid stromal component present in pleomorphic adenoma.
  • AIM: We report a case of basal cell adenoma of membranous type, highly suspected of malignancy because of the presence of mediastinal lymph nodes and pulmonary nodules which finally were related to an associated sarcoidosis.
  • So the diagnosis of metastatic malignant salivary gland tumor was suspected.
  • Finally, the histological examination concluded to a basal cell adenoma of membranous type with sarcoidosis granulomas in the parotid and in the lymph nodes.
  • CONCLUSION: The BCA is a benign tumor located generally in the parotid gland.
  • When the malignancy is suspected, like in our case, this tumor must be differentiated from the basal cell adenocarcinoma using histological criteria.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522450.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


Advertisement
4. Podetta M, D'Ambrosio G, Ferrari A, Sgarella A, Dal Bello B, Fossati GS, Zonta S, Silini E, Dionigi P: Low-grade fibromatosis-like spindle cell metaplastic carcinoma: a basal-like tumor with a favorable clinical outcome. Report of two cases. Tumori; 2009 Mar-Apr;95(2):264-7
MedlinePlus Health Information. consumer health - Mastectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade fibromatosis-like spindle cell metaplastic carcinoma: a basal-like tumor with a favorable clinical outcome. Report of two cases.
  • Fibromatosis-like spindle-cell metaplastic carcinoma (FLSpCC) is an atypical variant of spindle-cell carcinoma with a particular clinical behavior characterized by frequent local recurrence, very low potential for axillary lymph node metastasis, and uncommon distant metastases.
  • Although it presents the typical immunoprofile of basal-like carcinomas, FLSpCC is associated with a favorable clinical outcome and conservative treatment is generally indicated.
  • Because of the lack of specific clinical and radiological characteristics, the criteria for the differential diagnosis from other benign and malignant tumors are based only on histological findings and immunostaining.
  • [MeSH-minor] Aged. Aged, 80 and over. Axilla. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Lymph Node Excision. Metaplasia / diagnosis. Treatment Outcome

  • Genetic Alliance. consumer health - Fibromatosis.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19579879.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


5. Yang HM, Cabral E, Dadras SS, Cassarino DS: Immunohistochemical expression of D2-40 in benign and malignant sebaceous tumors and comparison to basal and squamous cell carcinomas. Am J Dermatopathol; 2008 Dec;30(6):549-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of D2-40 in benign and malignant sebaceous tumors and comparison to basal and squamous cell carcinomas.
  • The distinction of sebaceous carcinoma from benign sebaceous proliferations and other tumors is therefore of utmost importance, and immunohistochemistry may be useful in this differential.
  • A total of 36 cases of sebaceous lesions, including 16 sebaceous carcinomas, 7 sebaceous adenomas, 6 sebaceomas, and 7 cases of normal glands and sebaceous hyperplasia, and 17 cases of basal cell carcinoma and 10 cases of squamous cell carcinoma, were also examined.
  • We found no significant increase in tumor lymphangiogenesis by semiquantitative scoring of lymphovascular density per square millimeter of tumoral/peritumoral stroma in sebaceous carcinoma versus benign sebaceous proliferations.
  • However, D2-40 staining showed a different pattern in the benign tumors, which were positive only in the basaloid cells (most pronounced in sebaceoma), versus sebaceous carcinoma, which was either negative or focally positive in a haphazard pattern in most cases, although some cases of basaloid sebaceous carcinomas showed strong positivity.
  • We also found D2-40 to be only weakly and focally positive in basal cell carcinoma and weakly to moderately positive in squamous cell carcinoma, which showed increased staining with decreased differentiation.
  • Therefore, overall, D2-40 is, of limited diagnostic utility in sebaceous lesions but may be useful in distinguishing sebaceoma and basaloid sebaceous carcinoma from basal cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Sebaceous / metabolism. Antibodies, Monoclonal / metabolism. Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Sebaceous Gland Neoplasms / metabolism. Sebaceous Glands / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / metabolism. Adenoma / pathology. Antibodies, Monoclonal, Murine-Derived. Biomarkers, Tumor / metabolism. Case-Control Studies. Cell Proliferation. Diagnosis, Differential. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Hyperplasia / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19033927.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / monoclonal antibody D2-40
  •  go-up   go-down


6. Bornstein MM, Filippi A, Altermatt HJ, Lambrecht JT, Buser D: [The odontogenic keratocyst--odontogenic cyst or benign tumor?]. Schweiz Monatsschr Zahnmed; 2005;115(2):110-28
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The odontogenic keratocyst--odontogenic cyst or benign tumor?].
  • [Transliterated title] Die odontogene Keratozyste--odontogene Zyste oder benigner Tumor?
  • Multiple odontogenic keratocysts are a well-recognized feature of the nevoid basal cell carcinoma syndrome.
  • This led to the tentative suggestion that the keratocyst might be a benign cystic neoplasm rather than simply an odontogenic cyst.

  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771334.001).
  • [ISSN] 0256-2855
  • [Journal-full-title] Schweizer Monatsschrift fur Zahnmedizin = Revue mensuelle suisse d'odonto-stomatologie = Rivista mensile svizzera di odontologia e stomatologia
  • [ISO-abbreviation] Schweiz Monatsschr Zahnmed
  • [Language] FRE; GER
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 68238-35-7 / Keratins
  • [Number-of-references] 69
  •  go-up   go-down


7. Izikson L, Bhan A, Zembowicz A: Androgen receptor expression helps to differentiate basal cell carcinoma from benign trichoblastic tumors. Am J Dermatopathol; 2005 Apr;27(2):91-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgen receptor expression helps to differentiate basal cell carcinoma from benign trichoblastic tumors.
  • Histologic differentiation between basal cell carcinoma and benign trichoblastic neoplasms such as trichoepithelioma and trichoblastoma can be difficult on small biopsies.
  • Recent studies have shown androgen receptor expression in a number of mature epithelial structures in the skin and in epithelial neoplasms including basal cell carcinoma.
  • These findings suggested that androgen receptor expression might be a useful adjunct in the histologic differential diagnosis between basal cell carcinoma and benign trichoblastic neoplasms.
  • Therefore, we performed immunohistochemical analysis of androgen receptor expression in 32 basal cell carcinomas and 10 benign trichoblastic tumors (6 trichoepitheliomas and 4 trichoblastomas).
  • In our study, at least focal expression of androgen receptor was detected in 78% of basal cell carcinomas.
  • These results confirm the lack of expression of androgen receptor in benign trichoblastic neoplasms and indicate that androgen receptor expression by tumor cells points to basal cell carcinoma as the most likely diagnosis.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Hair Follicle / metabolism. Receptors, Androgen / biosynthesis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15798431.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Androgen
  •  go-up   go-down


8. Iczkowski KA, Montironi R: Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu. J Clin Pathol; 2006 Dec;59(12):1327-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu.
  • Adenoid cystic/basal cell carcinoma (ACBCC) is a rare neoplasm in the prostate.
  • Benign acini expressed HER-2/neu only in the basal layer.
  • The finding of strong, consistent HER-2/neu expression in ACBCC suggests that treatment with Herceptin (trastuzumab) may be effective in patients with this rare tumour.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Basal Cell / metabolism. Mixed Tumor, Malignant / metabolism. Prostatic Neoplasms / metabolism. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adult. Aged. Gene Expression. Humans. In Situ Hybridization. Male. Middle Aged. RNA, Messenger / genetics. RNA, Neoplasm / genetics


9. Saad RS, Liu YL, Silverman JF: Distribution of basal/myoepithelial markers in benign and malignant bronchioloalveolar proliferations of the lung. Appl Immunohistochem Mol Morphol; 2010 May;18(3):219-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of basal/myoepithelial markers in benign and malignant bronchioloalveolar proliferations of the lung.
  • We investigated the staining pattern of commonly used basal cell/myoepithelial markers, such as p63 (a p53-homologous nuclear protein), basal cell-specific cytokeratin antibody (34betaE12, K903), and smooth muscle myosin heavy chain (SMMHC) in benign and malignant bronchioloalveolar proliferations of the lung.
  • We studied 85 lung lesions consisting of 35 bronchioloalveolar carcinoma, 30 well-differentiated adenocarcinoma, and 20 cases of benign lung lesions.
  • In normal lung, p63, K903, and SMMHC decorated the basal cells of large and small airways and occasional cells of terminal bronchioles.
  • In reactive processes, a distinctive staining pattern was present in 19/20 (95%) of the cases characterized by staining of basal cells of the airways and bronchiolar epithelium and squamous metaplastic epithelium for p63 and K903, whereas 12/20 (60%) stained with SMMHC.
  • Our results highlighted the differential expression of basal cell markers across various bronchioloalveolar lesions.
  • The staining pattern of basal cells in bronchioloalveolar carcinoma supports that these neoplasms may actually be carcinoma in-situ.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065853.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins; EC 3.6.1.- / Smooth Muscle Myosins
  •  go-up   go-down


10. Weyers W, Hörster S, Diaz-Cascajo C: Tumor of follicular infundibulum is Basal cell carcinoma. Am J Dermatopathol; 2009 Oct;31(7):634-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor of follicular infundibulum is Basal cell carcinoma.
  • Tumor of follicular infundibulum (TFI) is currently thought to be a benign epithelial neoplasm with follicular differentiation.
  • It is encountered commonly in association with basal cell carcinoma (BCC), often as an incidental finding.
  • [MeSH-major] Carcinoma, Basal Cell / classification. Carcinoma, Basal Cell / pathology. Skin Neoplasms / classification. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19652582.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Katase N, Nagatsuka H, Tsujigiwa H, Gunduz M, Tamamura R, Pwint HP, Rivera RS, Nakajima M, Naomoto Y, Nagai N: Analysis of the neoplastic nature and biological potential of sporadic and nevoid basal cell carcinoma syndrome-associated keratocystic odontogenic tumor. J Oral Pathol Med; 2007 Oct;36(9):550-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the neoplastic nature and biological potential of sporadic and nevoid basal cell carcinoma syndrome-associated keratocystic odontogenic tumor.
  • BACKGROUND: Keratocystic odontogenic tumor (KCOT), also known as odontogenic keratocyst, is a benign cystic neoplasm, which may be associated with nevoid basal cell carcinoma syndrome (NBCCS) and if it does, will occur as multiple cystic lesions.
  • [MeSH-major] Basal Cell Nevus Syndrome / enzymology. Glucuronidase / biosynthesis. Odontogenic Cysts / enzymology. Odontogenic Tumors / enzymology
  • [MeSH-minor] Dentigerous Cyst / enzymology. Gene Expression Regulation, Neoplastic. Heparan Sulfate Proteoglycans / metabolism. Humans. Immunohistochemistry. In Situ Hybridization. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17850439.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Heparan Sulfate Proteoglycans; EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


12. Kawata R, Yoshimura K, Lee K, Araki M, Takenaka H, Tsuji M: Basal cell adenoma of the parotid gland: a clinicopathological study of nine cases--basal cell adenoma versus pleomorphic adenoma and Warthin's tumor. Eur Arch Otorhinolaryngol; 2010 May;267(5):779-83
Genetic Alliance. consumer health - Warthin's tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma of the parotid gland: a clinicopathological study of nine cases--basal cell adenoma versus pleomorphic adenoma and Warthin's tumor.
  • The aim of this study is to investigate the clinical and pathological characteristics of basal cell adenoma (BCA) and to compare the diagnosis/treatment of BCA with those of Warthin's tumor (WT) and pleomorphic adenoma (PA).
  • Among 192 patients with benign tumors of the parotid gland who underwent surgery, 9 had BCA.
  • All of these tumors showed a benign pattern on computed tomography and magnetic resonance imaging.
  • Considering the gender difference, tumor site, and age, it is necessary to differentiate BCA from PA rather than from WT.
  • BCA is the third most common of the benign parotid tumors, following WT and PA, although its incidence is low.
  • When PA and WT are ruled out by FNAB after a tentative diagnosis of benign tumor has been based on imaging findings, BCA should be considered.
  • [MeSH-minor] Adult. Aged. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19908055.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Jokinen CH, Wolgamot GM, Argenyi ZB: Collagen-rich variant of benign epithelioid peripheral nerve sheath tumor of the skin. J Cutan Pathol; 2008 Feb;35(2):215-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collagen-rich variant of benign epithelioid peripheral nerve sheath tumor of the skin.
  • Schwannoma and neurofibroma account for the majority of cutaneous benign peripheral nerve sheath tumors and usually pose little diagnostic difficulty in their classic forms.
  • In rare instances, however, benign peripheral nerve sheath tumors may display epithelioid morphology and lack otherwise usual features of schwannoma or neurofibroma, making classification difficult.
  • These unusual changes may prompt consideration of other benign neoplasms or a malignancy.
  • Benign epithelioid peripheral nerve sheath tumor (BEPNST) is a somewhat non-specific term recently proposed to describe these neoplasms of imprecise histogenesis.
  • Specifically, the neoplastic cells in this tumor were nearly obscured by the collagen, which formed large nodules and compressed the majority of the few remaining tumor cells to the periphery of the lesion.
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Microscopy, Electron, Transmission. Neck / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18190449.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 9007-34-5 / Collagen
  •  go-up   go-down


14. Chen WL, Yang ZH, Huang ZQ, Chai Q, Zhang DM: Facial contour reconstruction after benign tumor ablation using reverse facial-submental artery deepithelialized submental island flaps. J Craniofac Surg; 2010 Jan;21(1):83-6
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Facial contour reconstruction after benign tumor ablation using reverse facial-submental artery deepithelialized submental island flaps.
  • Reverse facial-submental artery deepithelialized submental island flaps were used for reconstructing facial contour deformities in 5 patients after benign tumor ablation.
  • Recurrent pleomorphic adenoma in the cheek and inferior temple was present in 3 patients, and recurrent basal cell adenoma was present in 1.
  • The flap can be used reliably for facial contour reconstruction of middle and upper facial contour deformities after benign tumor ablation in the cheek and inferior temple.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery. Reconstructive Surgical Procedures / methods. Surgical Flaps / blood supply
  • [MeSH-minor] Adult. Cheek. Female. Forehead. Humans. Male. Neoplasm Recurrence, Local / surgery. Postoperative Complications. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061969.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Weiler C, Reu S, Zengel P, Kirchner T, Ihrler S: Obligate basal cell component in salivary oncocytoma facilitates distinction from acinic cell carcinoma. Pathol Res Pract; 2009;205(12):838-42
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obligate basal cell component in salivary oncocytoma facilitates distinction from acinic cell carcinoma.
  • The differential diagnosis between benign salivary oncocytoma (ONC) and low-grade malignant acinic cell carcinoma (ACC) can be difficult due to a significant histomorphological overlap of the structural and cytological presentation of both tumor types.
  • The statistically significant stronger expression of CK7 in ONC and stronger expression of PAS and alpha-amylase in ACC in routine practice each is hampered by a pronounced overlap between both tumor groups.
  • The obligate presence of an additional small basal cell component in all cases of ONC, demonstrable with p63 and CK5/6, enables a straightforward distinction from ACC, being constantly devoid of a basal cell component.
  • Unexpectedly, CK14 is not a suitable marker for a reliable proof of these basal cells.
  • The detection of this basal cell component in ONC in routine Hematoxylin-eosin stain is difficult and in some cases not possible; therefore, immunohistochemistry with p63 or CK5/6 is recommended for selected cases.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Biomarkers, Tumor / analysis. Carcinoma, Acinar Cell / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-5 / analysis. Keratin-6 / analysis. Male. Middle Aged. Predictive Value of Tests. Trans-Activators / analysis. Transcription Factors. Tumor Suppressor Proteins / analysis

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19646823.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT5 protein, human; 0 / Keratin-5; 0 / Keratin-6; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


16. Seili-Bekafigo I, Jonjić N, Stemberger C, Rajković-Molek K: Additional cytomorphological criteria in diagnosis of pilomatricoma--benign tumor with bad reputation. Coll Antropol; 2010 Mar;34(1):117-22
Hazardous Substances Data Bank. METHYLENE BLUE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Additional cytomorphological criteria in diagnosis of pilomatricoma--benign tumor with bad reputation.
  • Pilomatricomas (PM) are benign skin appendageal tumors, with differentiation towards hair-forming cells, usually found in children.
  • PM are often mistaken for "small round blue cell" tumors in children, or for Merkel cell carcinoma, basalioma and metastatic small cell carcinoma in adults, with possible over-aggressive therapeutic approach.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Carcinoma, Basal Cell / pathology. Carcinoma, Merkel Cell / pathology. Child. Diagnosis, Differential. Eosine Yellowish-(YS). Epithelial Cells / pathology. Female. Humans. Male. Methylene Blue. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432739.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / May-Grunwald Giemsa; T42P99266K / Methylene Blue; TDQ283MPCW / Eosine Yellowish-(YS)
  •  go-up   go-down


17. Pham TT, Selim MA, Burchette JL Jr, Madden J, Turner J, Herman C: CD10 expression in trichoepithelioma and basal cell carcinoma. J Cutan Pathol; 2006 Feb;33(2):123-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10 expression in trichoepithelioma and basal cell carcinoma.
  • BACKGROUND: Trichoepithelioma (TE) is a benign neoplasm that shares both clinical and histologic features with basal cell carcinoma (BCC).
  • Cases were analyzed for pattern of CD10 expression by tumor cells and surrounding stroma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / metabolism. Neoplasms, Basal Cell / metabolism. Neprilysin / metabolism. Skin Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16420307.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


18. Ozcan C, Apa DD, Vayisoglu Y, Görür K: Unilateral parotid gland involvement with synchronous multiple Basal cell adenomas. J Craniofac Surg; 2007 Nov;18(6):1470-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral parotid gland involvement with synchronous multiple Basal cell adenomas.
  • Basal cell adenoma (BCA) is a rare benign epithelial tumor of the salivary gland.
  • The most commonly seen multiple tumor unilaterally or bilaterally is the Warthin's tumor.
  • More extensive excision of the parotid gland tumor, careful macroscopic perioperative examination of the surgical specimen, and histologic evaluation of all surgical specimens might be necessary for reducing revision operations and surgical complications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17993904.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Arshad AR, Azman WS, Kreetharan A: Solitary sebaceous nevus of Jadassohn complicated by squamous cell carcinoma and basal cell carcinoma. Head Neck; 2008 Apr;30(4):544-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary sebaceous nevus of Jadassohn complicated by squamous cell carcinoma and basal cell carcinoma.
  • BACKGROUND: Sebaceous nevus is a benign congenital epidermal nevus.
  • Its association with basal cell carcinoma is well known.
  • METHOD: This is a case report of sebaceous carcinoma complicated by both basal cell carcinoma and squamous cell carcinoma.
  • RESULTS: The behavior of this tumor is very aggressive, resulting in poor prognosis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Neoplasms, Multiple Primary / pathology. Nevus, Sebaceous of Jadassohn / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Fatal Outcome. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Surgical Flaps

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972311.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Asilian A, Tamizifar B: Aggressive and neglected basal cell carcinoma. Dermatol Surg; 2005 Nov;31(11 Pt 1):1468-71
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive and neglected basal cell carcinoma.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common cutaneous malignancy and usually has a benign coarse.
  • Rarely, examples of aggressive and neglected types of this tumor are seen.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Skin Neoplasms / pathology. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16416624.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Bohn OL, Rios-Luna NP, Navarro L, Duran-Peña A, Sanchez-Sosa S: Basal cell carcinoma of the prostate gland: a case report and brief review of the basal cell proliferations of the prostate gland. Ann Diagn Pathol; 2010 Oct;14(5):365-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the prostate gland: a case report and brief review of the basal cell proliferations of the prostate gland.
  • Basal cell proliferations within the prostate gland encompass a group of benign and malignant entities.
  • Although basal cell hyperplasia is a common finding, basal cell carcinoma of the prostate gland is a rare tumor that can be mistaken by a benign condition and represents a diagnostic problem in genitourinary pathology.
  • We report a case of basal cell carcinoma in a previously healthy 65-year-old man with urinary symptoms and low prostate-specific antigen.
  • The microscopic findings are presented and the use of immunohistochemical markers classifying basal cell lesions of the prostate discussed.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / diagnosis. Prostatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20850702.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


22. Hagemann T, Binder C, Binder L, Pukrop T, Trümper L, Grimshaw MJ: Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells. DNA Cell Biol; 2005 Nov;24(11):766-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells.
  • There is increased staining of endothelins (ET-1, -2, and -3) and receptors (ET-RA and -RB) in invasive breast tumors compared to nonneoplastic tissue, and ETs stimulate MCF-7 cell invasion in vitro.
  • We analyzed ETstimulation of benign and transformed mammary epithelial cells, and whether expression of ETs is sufficient to induce invasiveness.
  • In breast cancer patient serum, ET-1 was increased in those patients with lymph node metastases compared to those with no lymph node involvement; ETs, however, had no mitogenic effect on breast tumor cell lines in vitro.
  • The benign mammary epithelial cell line, hTERT-HME1, and the poorly invasive breast tumor cell line MCF-7 secreted low levels of ET-1, while the invasive cell lines SKBR3 and MDAMB231 secreted high levels.
  • Expression of the ETs and receptors by the cell lines broadly correlated with their in vitro invasiveness; overexpression of ETs in MCF-7 cells increased basal invasion.
  • In contrast to transformed cells, ET stimulation or overexpression did not induce an invasive phenotype in benign cells.
  • Benign cells do not respond to ETs, and ET expression is not sufficient to induce invasion; however, the level of ET production by tumor cells correlates with their invasiveness, and increasing expression of the ET axis promotes breast tumor cell invasion via both receptors, while MMP-14 is induced via ET-RA.
  • [MeSH-minor] Calcium / metabolism. Cell Line. Cell Line, Tumor. Endothelin-1 / blood. Endothelin-1 / metabolism. Enzyme Induction. Female. Humans. Lymphatic Metastasis. Mammary Glands, Human / metabolism. Mammary Glands, Human / pathology. Matrix Metalloproteinases / biosynthesis. Neoplasm Invasiveness. Phenotype. Signal Transduction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16274297.001).
  • [ISSN] 1044-5498
  • [Journal-full-title] DNA and cell biology
  • [ISO-abbreviation] DNA Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endothelin-1; 0 / Endothelins; 0 / Receptor, Endothelin A; 0 / Receptor, Endothelin B; EC 3.4.24.- / Matrix Metalloproteinases; SY7Q814VUP / Calcium
  •  go-up   go-down


23. McGregor DH, Cherian R, Romanas MM, Ulusarac O, Mathur SC, Feldman MM: Amelanotic malignant melanoma: two collision tumors presenting as basal cell carcinoma and atypical fibroxanthoma. Ann Clin Lab Sci; 2008;38(2):157-62
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amelanotic malignant melanoma: two collision tumors presenting as basal cell carcinoma and atypical fibroxanthoma.
  • One patient is a 79-yr-old male with an 8.7 x 5.5 x 4.5 cm polypoid lesion that on shave biopsy was diagnosed as basal cell carcinoma.
  • Subsequent excision showed that the lesion was largely composed of amelanotic melanoma underlying a relatively small and thin basal cell carcinoma, and this probably would have been demonstrated in a punch (rather than shave) biopsy.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Histiocytoma, Benign Fibrous / diagnosis. Melanoma, Amelanotic / diagnosis. Neoplasms, Multiple Primary / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Immunohistochemistry. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469362.001).
  • [ISSN] 1550-8080
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  •  go-up   go-down


24. Bernardini FP: Management of malignant and benign eyelid lesions. Curr Opin Ophthalmol; 2006 Oct;17(5):480-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of malignant and benign eyelid lesions.
  • PURPOSE OF REVIEW: The management of benign and malignant eyelid neoplasms has been extensively examined.
  • RECENT FINDINGS: Recent studies have focused on the results of nonsurgical approaches for benign and premalignant lesions that are routinely surgically excised.
  • In the malignant group, a consensus has been reached over the preferred method of tumor excision for basal cell carcinoma: Mohs surgery or complete surgical excision with frozen-section control of the margins offers the lowest tumor-recurrence rate.
  • Intraepithelial tumor growth is a peculiar feature of sebaceous gland carcinoma that seems to indicate an increased risk for orbital invasion.
  • Recent reports regarding the rare tumor, Merkel cell carcinoma, recommend a wide surgical excision with 5 mm margins; this may reduce the incidence of lymph-node metastasis, haematogenous spread and local recurrences.
  • SUMMARY: Although treatment of the most common benign and malignant tumours affecting the eyelids has not radically changed over the years, recent reports have significantly improved the standard of care for affected patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16932064.001).
  • [ISSN] 1040-8738
  • [Journal-full-title] Current opinion in ophthalmology
  • [ISO-abbreviation] Curr Opin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


25. Kuratomi Y, Satoh S, Hayashida S, Inokuchi A: Basal cell adenoma and lymphoepithelial cyst as recurrent tumors of pleomorphic adenoma of the parotid gland. Auris Nasus Larynx; 2006 Mar;33(1):97-100

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma and lymphoepithelial cyst as recurrent tumors of pleomorphic adenoma of the parotid gland.
  • Basal cell adenoma of the parotid gland is a rare benign tumor.
  • Lymphoepithelial cyst of the parotid gland is also a rare benign tumor-like lesion.
  • The histological examination revealed that the masses were two basal cell adenomas and one lymphoepithelial cyst.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16171964.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


26. Obata H, Aoki Y, Kubota S, Kanai N, Tsuru T: [Incidence of benign and malignant lesions of eyelid and conjunctival tumors]. Nippon Ganka Gakkai Zasshi; 2005 Sep;109(9):573-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidence of benign and malignant lesions of eyelid and conjunctival tumors].
  • PURPOSE: To examine the incidence of benign and malignant eyelid lesions and conjunctival tumors.
  • The incidence of benign or malignant lesions, the pathological classification, age, sex, and clinical diagnostic accuracy were all investigated.
  • RESULTS: Sixty-four (73%) of the tumors were found to be benign eyelid tumors.
  • The common benign eyelid tumors were 14 nevocellular nevi, 9 seborrheic keratosis, 7 epidermoid cysts, and 6 papillomas.
  • These included 9 basal cell carcinomas, 9 sebaceous gland carcinomas, 4 malignant lymphomas, and 2 metastatic tumors.
  • Thirty-four (79%) conjunctival tumors were benign, and the common benign conjunctival tumors were 9 nevocellular nevi and 7 papillomas.
  • Nine (21%) conjunctival tumors were malignant, comprising 7 malignant lymphomas and 2 squamous cell carcinomas.
  • The mean ages of malignant eyelid and conjunctival tumor patients were significantly older than those of benign tumor patients.
  • Clinical accuracy in predicting basal cell carcinoma and sebaceous gland carcinoma was 11.1% and 44.4%, respectively.
  • CONCLUSIONS: Approximately 70 approximately 80% of all eyelid and conjunctival tumors are benign.
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Female. Humans. Incidence. Lymphoma / epidemiology. Lymphoma / pathology. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16218435.001).
  • [ISSN] 0029-0203
  • [Journal-full-title] Nippon Ganka Gakkai zasshi
  • [ISO-abbreviation] Nippon Ganka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 27
  •  go-up   go-down


27. Puizina-Ivić N, Sapunar D, Marasović D, Mirić L: An overview of Bcl-2 expression in histopathological variants of basal cell carcinoma, squamous cell carcinoma, actinic keratosis and seborrheic keratosis. Coll Antropol; 2008 Oct;32 Suppl 2:61-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An overview of Bcl-2 expression in histopathological variants of basal cell carcinoma, squamous cell carcinoma, actinic keratosis and seborrheic keratosis.
  • The Bcl-2 protein has been shown to suppress cell death and protects cell against apoptosis induced by different death-inducing signals.
  • In this study the authors have analyzed imunohistochemically the expression of Bcl-2 protein in the histopathological variants of the most common malignant tumors of the skin--basal cell carcinoma (BCC) and squamous cell tumor (SCC), as well as in the precancerous lesion actinic keratosis (AK) and in benign tumor seborrheic keratosis (SK).
  • Bcl-2 expression in solid, adenoid and cystic variants of BCC exhibited immunoreactivity of tumor stroma with more intense staining among peripheral palisading cells.
  • Among SCC in all samples, tumor tissue lack to express Bcl-2 positivity.
  • In cases of hypertrophic and atrophic variants of AK, Bcl-2 expression was confined to basal cell layer, as well as in one case of hypertrophic variant in suprabasal cells.
  • In clonal variant immunostaining was positive among cells in characteristic "nests" Distribution of Bcl-2 protein expression in solid, adenoid and cystic variant of BCC showed that peripheral proliferating cells are protected against apoptosis what permits tumor growth.
  • In morpheaform variant reduced amount of Bcl-2 expression indicated that this variant of BCC has increased cell proliferation, and in practice shows tendency for recurrence and difficulties to eradicate.
  • Bcl-2 expression supports the observation that tumor cells are derived from basal keratinocytes.
  • In SCC, lack of Bcl-2 expression indicates that origin of tumor cells is from more differentiated suprabasal keratinocytes.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Keratosis, Actinic / metabolism. Keratosis, Seborrheic / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Skin Neoplasms / metabolism


28. Bossert T, Walther T, Vondrys D, Gummert JF, Kostelka M, Mohr FW: Cardiac fibroma as an inherited manifestation of nevoid basal-cell carcinoma syndrome. Tex Heart Inst J; 2006;33(1):88-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac fibroma as an inherited manifestation of nevoid basal-cell carcinoma syndrome.
  • Echocardiography revealed a left ventricular tumor.
  • The tumor was resected through a left ventriculotomy, and the left ventricle was reconstructed after a partial ventriculectomy Histologic investigation showed a completely resected benign fibroma.
  • The 30-year-old mother was known to have nevoid basal-cell carcinoma syndrome, which can be associated with cardiac fibromas.

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2001 Apr;71(4):1354-6 [11308193.001]
  • [Cites] Ann Thorac Surg. 2003 Apr;75(4):1306-8 [12683582.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1986 Jul;112(7):773-5 [3707741.001]
  • [Cites] Medicine (Baltimore). 1987 Mar;66(2):98-113 [3547011.001]
  • [Cites] Am Heart J. 1997 Dec;134(6):1107-14 [9424072.001]
  • [Cites] Pediatr Cardiol. 1991 Apr;12(2):118-20 [1866331.001]
  • [Cites] J Med Genet. 1993 Jun;30(6):460-4 [8326488.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Nov;108(5):862-70 [7967668.001]
  • [Cites] J Heart Lung Transplant. 1995 Mar-Apr;14(2):382-6 [7779860.001]
  • [Cites] Thorac Cardiovasc Surg. 1990 Aug;38 Suppl 2:176-82 [2237899.001]
  • (PMID = 16572881.001).
  • [ISSN] 0730-2347
  • [Journal-full-title] Texas Heart Institute journal
  • [ISO-abbreviation] Tex Heart Inst J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1413607
  •  go-up   go-down


29. Stoebner PE, Le Gallic L, Berthe ML, Boulle N, Lallemant B, Marque M, Gaspard C, Delfour C, Lavabre-Bertrand T, Martinez J, Meunier L: Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas. Exp Dermatol; 2008 Nov;17(11):908-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas.
  • Thymidine phosphorylase (TP)/platelet-derived endothelial cell growth factor is associated with tumor angiogenesis.
  • We evaluated the TP mRNA and protein expression in basal cell carcinomas (BCC) and in various skin tumors including numerous BCC histological simulants.
  • TP mRNA levels were measured by real time RT-PCR in whole BCCs (wBCC) and laser capture microdissected (LCM) BCC tumor cells.
  • TP immunostaining was negative in all BCC variants and in most of the benign trichogeneic tumors studied.
  • By contrast, TP was constantly immunodetected in actinic keratosis (AK), squamous cell carcinomas (SCC), syringomatous carcinomas (SC), basosquamous carcinomas (BSC) and melanomas.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology. Thymidine Phosphorylase / genetics
  • [MeSH-minor] Carcinoma, Basosquamous / genetics. Carcinoma, Basosquamous / metabolism. Carcinoma, Basosquamous / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Down-Regulation. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Keratosis, Actinic / genetics. Keratosis, Actinic / metabolism. Keratosis, Actinic / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341568.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.4.2.4 / Thymidine Phosphorylase
  •  go-up   go-down


30. Ghaderi R, Haghighi F: Immunohistochemistry assessment of p53 protein in Basal cell carcinoma. Iran J Allergy Asthma Immunol; 2005 Dec;4(4):167-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry assessment of p53 protein in Basal cell carcinoma.
  • The most frequently mutated tumor suppressor gene found in human cancer is p53.
  • In a normal situation, p53 is activated upon the induction of DNA damage to either arrest the cell cycle or else induce apoptosis.
  • Our aim was to investigate p53 protein alteration in cases of basal cell carcinoma (BCC) and compare it with the control group.
  • We investigated P53 gene expression in 41 cases of basal cell carcinoma and 20 patients with benign skin disease as control group.
  • The Data were analyzed using SPSS package, T and Chi-Square tests.Twenty eight out of 41 basal cell carcinoma and 3 out of 20 control were p53-mutated, and there was a statistically significant difference in cases of BCC in comparison with controls (x2 test; p= 0.0001).Taken together, showing alteration of p53 protein, our findings could add to the knowledge that might contribute to the self-maintenance of cancer cells and development of basal cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301441.001).
  • [ISSN] 1735-1502
  • [Journal-full-title] Iranian journal of allergy, asthma, and immunology
  • [ISO-abbreviation] Iran J Allergy Asthma Immunol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


31. Krajewska M, Olson AH, Mercola D, Reed JC, Krajewski S: Claudin-1 immunohistochemistry for distinguishing malignant from benign epithelial lesions of prostate. Prostate; 2007 Jun 15;67(9):907-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin-1 immunohistochemistry for distinguishing malignant from benign epithelial lesions of prostate.
  • BACKGROUND: Claudins are a family of approximately 23 integral membrane tight junction (TJ) proteins that maintain cell polarity and paracellular barrier functions in epithelial and endothelial cells.
  • METHODS: Using immunohistochemistry, the expression of Claudin-1 was investigated in prostate tissue samples arranged in a tissue microarray (TMA) format and comprising elements of normal prostatic epithelium (n = 6), benign prostatic hyperplasia (BPH; n = 38), prostatic intraepithelial neoplasia (PIN; n = 11), and prostate adenocarcinoma (n = 48).
  • The Claudin-1 expression pattern was compared with that of the basal cell-specific markers, p63, and HMW cytokeratin (34betaE12), by employing double-labeling techniques in conjunction with image analysis methods utilizing color deconvolution algorithms.
  • RESULTS: In benign prostatic epithelium, pronounced Claudin-1 expression was observed in the basal cell layer with no staining in luminal cells.
  • Prostate adenocarcinoma specimens from 98% (47/48) patients lacked Claudin-1 immunostaining, and no cases contained >5% immunopositive tumor cells.
  • CONCLUSIONS: Claudin-1 immunohistochemistry should be considered for use as a new diagnostic tool for distinguishing malignant from benign lesions of the prostate.

  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17440968.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA114810; United States / NCI NIH HHS / CA / CA114810-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / CLDN1 protein, human; 0 / Claudin-1; 0 / Membrane Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


32. Davari P, Hebert JL, Albertson DG, Huey B, Roy R, Mancianti ML, Horvai AE, McDaniel LD, Schultz RA, Epstein EH Jr: Loss of Blm enhances basal cell carcinoma and rhabdomyosarcoma tumorigenesis in Ptch1+/- mice. Carcinogenesis; 2010 Jun;31(6):968-73
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of Blm enhances basal cell carcinoma and rhabdomyosarcoma tumorigenesis in Ptch1+/- mice.
  • Basal cell carcinomas (BCCs) have relative genomic stability and relatively benign clinical behavior but whether these two are related causally is unknown.
  • The mutant Blm alleles also markedly enhanced the formation of rhabdomyosarcomas (RMSs), another cancer to which Ptch1(+/)(-) mice and PTCH1(+/)(-) (basal cell nevus syndrome) patients are susceptible.
  • Highly recurrent but different copy number changes were associated with the two tumor types and included losses of chromosomes 4 and 10 in all BCCs and gain of chromosome 10 in 80% of RMSs.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):71-83 [17943968.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10103-5 [17974949.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):743-54 [18813320.001]
  • [Cites] Dermatol Surg. 2009 Jan;35(1):131-4 [19076197.001]
  • [Cites] BMC Cancer. 2009;9:140 [19432957.001]
  • [Cites] Cancer Res. 2009 Jul 15;69(14):5768-75 [19584276.001]
  • [Cites] Nat Rev Cancer. 2009 Sep;9(9):644-54 [19657341.001]
  • [Cites] Leuk Res. 2010 Feb;34(2):210-20 [19709744.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] Nat Genet. 2000 Dec;26(4):424-9 [11101838.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):741-6 [11257107.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2000;1:409-59 [11701636.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):6-7 [11753379.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):727-33 [12016144.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2013 [12242432.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2051-3 [12242442.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):5-6 [12509771.001]
  • [Cites] Hum Mol Genet. 2003 Nov 1;12(21):2837-44 [12952869.001]
  • [Cites] Curr Mol Med. 2003 Nov;3(7):589-96 [14601634.001]
  • [Cites] DNA Repair (Amst). 2003 Dec 9;2(12):1387-404 [14642567.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8578-81 [14695165.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4385-9 [15231643.001]
  • [Cites] Science. 1983 Aug 26;221(4613):851-3 [6879180.001]
  • [Cites] Hum Genet. 1985;71(3):187-91 [4065890.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jan;86(2):670-4 [2911598.001]
  • [Cites] Medicine (Baltimore). 1993 Nov;72(6):393-406 [8231788.001]
  • [Cites] J Biol Chem. 1994 Nov 25;269(47):29838-45 [7961977.001]
  • [Cites] Nucleic Acids Res. 1994 Nov 11;22(22):4566-73 [7527136.001]
  • [Cites] Cell. 1995 Nov 17;83(4):655-66 [7585968.001]
  • [Cites] Science. 1996 Apr 12;272(5259):258-62 [8602509.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Jan;93(1):100-6 [9062585.001]
  • [Cites] Genes Dev. 1998 Nov 1;12(21):3382-93 [9808625.001]
  • [Cites] Oncogene. 1998 Nov 19;17(20):2565-71 [9840919.001]
  • [Cites] Genomics. 1998 Dec 15;54(3):443-52 [9878247.001]
  • [Cites] Genome Res. 2005 Feb;15(2):302-11 [15687294.001]
  • [Cites] Int J Oncol. 2005 Dec;27(6):1567-75 [16273213.001]
  • [Cites] N Engl J Med. 2005 Nov 24;353(21):2262-9 [16306523.001]
  • [Cites] J Med Genet. 2006 Feb;43(2):148-52 [15964893.001]
  • [Cites] Nucleic Acids Res. 2006;34(8):e58 [16670425.001]
  • [Cites] BMC Cancer. 2006;6:96 [16620391.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6606-14 [16818633.001]
  • [Cites] EMBO J. 2006 Jul 26;25(14):3422-31 [16858412.001]
  • [Cites] Mol Cell Biol. 2006 Sep;26(17):6713-26 [16914751.001]
  • [Cites] Cell. 2006 Nov 17;127(4):679-95 [17110329.001]
  • [Cites] J Cell Biol. 2007 Jul 2;178(1):9-14 [17591918.001]
  • [Cites] Mol Cancer Res. 2007 Jul;5(7):713-24 [17634426.001]
  • [Cites] Cell Mol Life Sci. 2007 Sep;64(17):2306-22 [17571213.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3558-60; discussion 3560-1 [18483234.001]
  • (PMID = 19995795.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA81888; United States / NCI NIH HHS / CA / CA84118
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.6.1.- / Bloom syndrome protein; EC 3.6.4.12 / RecQ Helicases
  • [Other-IDs] NLM/ PMC2878356
  •  go-up   go-down


33. Bordbar A, Dias D, Cabral A, Beck S, Boon ME: Assessment of cell proliferation in benign, premalignant and malignant skin lesions. Appl Immunohistochem Mol Morphol; 2007 Jun;15(2):229-35
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of cell proliferation in benign, premalignant and malignant skin lesions.
  • A deeper understanding of the variance of epidermal cell proliferation may eventually increase the reproducibility of diagnostic classification.
  • A prospective study of 46 consecutive, unselected biopsies from benign (keratoacanthoma n=14), premalignant (actinic keratosis n=15 and Bowen disease n=10) and malignant (squamous cell carcinoma n=7) skin lesions was studied to assess the presence and extent of differences in expression of the proliferation marker Ki-67 using a monoclonal antibody directed against a c-DNA defined subsegment (MIB-1) and a noncross-linking, proprietary fixative BoonFix.
  • MIB-1 was expressed in the adjacent, non-affected skin in a scattered to confluent linear pattern in the basal/suprabasal cell layer.
  • In actinic keratosis, MIB-1 expression, in addition to basal/suprabasal layers, extended to mid-zones of the epidermis.
  • In invasive squamous cell carcinoma, MIB-1 expression was not consistent between and within cases.
  • Keratoacanthoma cases showed highly variable MIB-1 expression, ranging from no expression to expression in both basal/suprabasal and mid-zone layers of the epidermis.
  • These results warrant further study of modulation of cell proliferation in actinic keratosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525640.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / MIB-1 antibody
  •  go-up   go-down


34. He X, Marchionni L, Hansel DE, Yu W, Sood A, Yang J, Parmigiani G, Matsui W, Berman DM: Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells; 2009 Jul;27(7):1487-95
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma.
  • Highly tumorigenic cancer cell (HTC) populations have been identified for a variety of solid tumors and assigned stem cell properties.
  • We identified a highly tumorigenic UC cell compartment that resembles benign urothelial stem cells (basal cells), co-expresses the 67-kDa laminin receptor and the basal cell-specific cytokeratin CK17, and lacks the carcinoembryonic antigen family member CEACAM6 (CD66c).
  • This multipotent compartment resides at the tumor-stroma interface, is easily identified on histologic sections, and possesses most, if not all, of the engraftable tumor-forming ability in the parental xenograft.
  • We analyzed differential expression of genes and pathways in basal-like cells versus more differentiated cells.
  • The basal/HTC gene expression signature was essentially invisible within the context of nontumorigenic cell gene expression and overlapped significantly with genes driving progression and death in primary human UC.
  • The spatially restricted epithelial differentiation program described here represents a conceptual advance in understanding cellular heterogeneity of carcinomas and identifies basal-like HTCs as attractive targets for cancer therapy.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Oct 1;67(19):8985-8 [17908998.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9199-206 [17909025.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:675-99 [17645413.001]
  • [Cites] Hum Pathol. 2007 Nov;38(11):1703-13 [17707461.001]
  • [Cites] Development. 2007 Dec;134(23):4255-63 [17978005.001]
  • [Cites] Sci Signal. 2008;1(8):pe10 [18314504.001]
  • [Cites] Cell Res. 2008 May;18(5):523-7 [18392048.001]
  • [Cites] Am J Physiol Renal Physiol. 2008 Jun;294(6):F1415-21 [18367656.001]
  • [Cites] Cancer Invest. 2008 Aug;26(7):725-33 [18608209.001]
  • [Cites] Oncogene. 2008 Sep 1;27(38):5124-31 [18758481.001]
  • [Cites] Mol Cancer Ther. 2008 Sep;7(9):2672-80 [18790749.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):755-68 [18784658.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9551-7 [19010932.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 3;100(23):1672-94 [19033571.001]
  • [Cites] Oncogene. 2008 Dec 4;27(57):7180-91 [18794802.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8010-8 [19088017.001]
  • [Cites] Nat Chem Biol. 2009 Feb;5(2):100-7 [19125156.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Nat Genet. 2000 May;25(1):25-9 [10802651.001]
  • [Cites] Am J Physiol Renal Physiol. 2000 Jun;278(6):F867-74 [10836974.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1516-22 [11410485.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Int J Oncol. 2002 May;20(5):905-11 [11956582.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):90-6 [12469123.001]
  • [Cites] Novartis Found Symp. 2002;247:91-101; discussion 101-3, 119-28, 244-52 [12539951.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):493-504 [12875970.001]
  • [Cites] Methods. 2003 Dec;31(4):265-73 [14597310.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):4040-8 [15173019.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] J Clin Pathol. 1967 Jan;20(1):7-14 [6016890.001]
  • [Cites] Virchows Arch B Cell Pathol. 1976 Oct 1;21(4):279-98 [824809.001]
  • [Cites] J Invest Dermatol. 1983 Jul;81(1 Suppl):109s-15s [6190956.001]
  • [Cites] Blood. 1990 May 15;75(10):1947-50 [2337669.001]
  • [Cites] Cancer. 1990 Aug 1;66(3):537-42 [2364364.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Oncogene. 1999 May 6;18(18):2883-91 [10362259.001]
  • [Cites] J Urol. 1999 Sep;162(3 Pt 1):931-5 [10458411.001]
  • [Cites] J Oral Pathol Med. 2005 Feb;34(2):116-9 [15641992.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3790-8 [15897578.001]
  • [Cites] Hum Pathol. 2005 May;36(5):522-30 [15948119.001]
  • [Cites] Methods Mol Med. 2005;103:89-101 [15542899.001]
  • [Cites] Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S183-7 [16113095.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):744-9 [16148886.001]
  • [Cites] Trends Cell Biol. 2005 Sep;15(9):494-501 [16084092.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):383-91 [16428476.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1554-9 [16261162.001]
  • [Cites] Cell Stem Cell. 2009 Mar 6;4(3):203-5 [19265659.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2109-16 [16609023.001]
  • [Cites] Am J Clin Pathol. 2006 Dec;126(6):849-55 [17074684.001]
  • [Cites] Nat Genet. 2006 Dec;38(12):1386-96 [17099711.001]
  • [Cites] Acta Haematol. 2007;117(1):8-15 [17095854.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] N Engl J Med. 2007 Jan 18;356(3):217-26 [17229949.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4407-14 [17671123.001]
  • [Cites] J Med Chem. 2008 Dec 11;51(23):7405-16 [18989950.001]
  • (PMID = 19544456.001).
  • [ISSN] 1549-4918
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA088843; United States / NCI NIH HHS / CA / P50CA088843; United States / NIDDK NIH HHS / DK / R01DK072000; United States / NIDDK NIH HHS / DK / R01 DK072000-04; United States / NIDDK NIH HHS / DK / K08 DK059375; United States / NCI NIH HHS / CA / P01CA077664; United States / NCI NIH HHS / CA / K23 CA107040; United States / NIDDK NIH HHS / DK / R01 DK072000; United States / NIDDK NIH HHS / DK / DK072000-04; United States / NCRR NIH HHS / RR / 1U54RR023561-01A1; United States / NIDDK NIH HHS / DK / K08DK059375; United States / NCI NIH HHS / CA / P01 CA077664; United States / NCI NIH HHS / CA / K23 CA107040-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CEACAM6 protein, human; 0 / Cell Adhesion Molecules; 0 / GPI-Linked Proteins; 0 / Receptors, Laminin
  • [Other-IDs] NLM/ NIHMS236727; NLM/ PMC3060766
  •  go-up   go-down


35. Klonisch T, Müller-Huesmann H, Riedel M, Kehlen A, Bialek J, Radestock Y, Holzhausen HJ, Steger K, Ludwig M, Weidner W, Hoang-Vu C, Hombach-Klonisch S: INSL3 in the benign hyperplastic and neoplastic human prostate gland. Int J Oncol; 2005 Aug;27(2):307-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] INSL3 in the benign hyperplastic and neoplastic human prostate gland.
  • In the present study we have investigated the expression of human INSL3 in patients with benign prostate hyperplasia (BPH), prostate intraepithelial neoplasia (PIN) and prostate carcinoma tissues.
  • Of the prostate epithelial cells, strongest INSL3 expression was detected in the basal epithelial cell compartment.
  • Three human prostate carcinoma cell lines displayed differential gene activity for INSL3 and LGR8.
  • While LNCaP was devoid of INSL3, the androgen-insensitive PC-3 and the stromal prostate cell line hPCP co-expressed INSL3 and LGR8 transcripts.
  • Instead, PC-3 responded to INSL3 with significantly enhanced tumor cell motility and a transcriptional down-regulation of ErbB receptors and EGF.
  • [MeSH-minor] Cell Line, Tumor. Cell Movement / drug effects. Cell Proliferation / drug effects. Cell Survival / drug effects. Cyclic AMP / metabolism. Dose-Response Relationship, Drug. Epidermal Growth Factor / pharmacology. Epithelial Cells / drug effects. Epithelial Cells / metabolism. Gene Expression / drug effects. Humans. Immunohistochemistry. In Situ Hybridization. Male. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, G-Protein-Coupled / analysis. Receptors, G-Protein-Coupled / genetics. Recombinant Proteins / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Tretinoin / pharmacology


36. Chiu NC, Wu HM, Chou YH, Li WY, Chiou YY, Guo WY, Chang CY: Basal cell adenoma versus pleomorphic adenoma of the parotid gland: CT findings. AJR Am J Roentgenol; 2007 Nov;189(5):W254-61
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma versus pleomorphic adenoma of the parotid gland: CT findings.
  • OBJECTIVE: Basal cell adenoma is a rare benign epithelial tumor of the salivary gland.
  • The objective of this study is to present the CT findings of parotid basal cell adenoma.
  • We also compare CT findings of basal cell adenoma with those of pleomorphic adenoma, the most common parotid tumor, to determine whether any features on CT can help differentiate these two entities.
  • CONCLUSION: Basal cell adenomas of the parotid gland are located chiefly in the superficial lobe.
  • The age of the patient and the attenuation on unenhanced and contrast-enhanced CT may help in differentiating basal cell adenoma from pleomorphic adenoma of the parotid gland.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954621.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Knight JF, Shepherd CJ, Rizzo S, Brewer D, Jhavar S, Dodson AR, Cooper CS, Eeles R, Falconer A, Kovacs G, Garrett MD, Norman AR, Shipley J, Hudson DL: TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer. Br J Cancer; 2008 Dec 02;99(11):1849-58
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer.
  • The disease may involve the inappropriate expression of genes that normally control the proliferation of epithelial cells in the basal layer and their differentiation into luminal cells.
  • Our aim was to identify novel basal cell markers and assess their prognostic and functional significance in prostate cancer.
  • RNA from basal and luminal cells isolated from benign tissue by immunoguided laser-capture microdissection was subjected to expression profiling.
  • We identified 112 and 267 genes defining basal and luminal populations, respectively.
  • The transcription factor TEAD1 and the ubiquitin ligase c-Cbl were identified as novel basal cell markers.
  • Knockdown of either marker using siRNA in prostate cell lines led to decreased cell growth in PC3 and disrupted acinar formation in a 3D culture system of RWPE1.
  • These data are consistent with basal features impacting on the development and clinical course of prostate cancers.
  • [MeSH-major] Biomarkers, Tumor / analysis. DNA-Binding Proteins / biosynthesis. Nuclear Proteins / biosynthesis. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Proto-Oncogene Proteins c-cbl / biosynthesis. Transcription Factors / biosynthesis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Biol Cell. 2000 Oct;11(10):3397-410 [11029044.001]
  • [Cites] Clin Exp Metastasis. 2004;21(7):571-9 [15787094.001]
  • [Cites] Prostate. 2001 Feb 1;46(2):142-53 [11170142.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):10413-22 [11136726.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Apr;2(4):294-307 [11283727.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 11):2167-78 [11493652.001]
  • [Cites] Mol Cell. 2001 Nov;8(5):995-1004 [11741535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11355-60 [16051706.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] J Cell Physiol. 2006 Oct;209(1):21-43 [16741904.001]
  • [Cites] Oncogene. 2006 Oct 19;25(49):6528-37 [16751809.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):528-36 [17234760.001]
  • [Cites] Differentiation. 2007 Jan;75(1):35-48 [17244020.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):159-66 [17361204.001]
  • [Cites] Oncogene. 2007 Mar 15;26(12):1757-68 [16964284.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5221-30 [17545602.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6796-805 [17638891.001]
  • [Cites] Mol Biol Cell. 2007 Jul;18(7):2481-90 [17475774.001]
  • [Cites] Oncogene. 2007 Sep 13;26(42):6238-43 [17369840.001]
  • [Cites] Expert Rev Mol Diagn. 2007 Sep;7(5):647-57 [17892370.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2747-61 [17974916.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6579-84 [18006757.001]
  • [Cites] Oncogene. 2008 Jan 10;27(3):253-63 [17637754.001]
  • [Cites] Dev Cell. 2008 Mar;14(3):377-87 [18258485.001]
  • [Cites] Dev Cell. 2008 Mar;14(3):388-98 [18258486.001]
  • [Cites] Dev Cell. 2008 Mar;14(3):315-6 [18331708.001]
  • [Cites] Mol Cell Biol. 2008 May;28(10):3177-89 [18332127.001]
  • [Cites] Prostate. 2008 Jun 15;68(9):1007-24 [18398820.001]
  • [Cites] BMC Genomics. 2008;9:246 [18501003.001]
  • [Cites] Prostate. 2008 Aug 1;68(11):1215-22 [18500693.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5146-52 [16033829.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2220-6 [11956072.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48889-98 [12376544.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19286-91 [12637527.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):464-9 [14695896.001]
  • [Cites] Eur Urol. 2004 Aug;46(2):271-2 [15245824.001]
  • [Cites] J Histochem Cytochem. 2004 Aug;52(8):1083-90 [15258184.001]
  • [Cites] Oncogene. 2004 Aug 5;23(35):5871-9 [15184867.001]
  • [Cites] Adv Cancer Res. 2004;91:31-67 [15327888.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6940-4 [1458483.001]
  • [Cites] J Urol. 1993 Jan;149(1):170-3 [7678041.001]
  • [Cites] Cell. 1993 Nov 19;75(4):805-16 [8242751.001]
  • [Cites] Oncogene. 1994 Oct;9(10):2785-91 [8084583.001]
  • [Cites] J Cell Biol. 1995 Mar;128(6):1019-28 [7896868.001]
  • [Cites] J Urol. 1995 Jul;154(1):293-8 [7539865.001]
  • [Cites] Arch Dermatol Res. 1995;287(8):740-6 [8554386.001]
  • [Cites] Prostate. 1996 Feb;28(2):98-106 [8604398.001]
  • [Cites] Mol Cell Biol. 1997 Jul;17(7):3924-36 [9199327.001]
  • [Cites] Carcinogenesis. 1997 Jun;18(6):1225-31 [9214606.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):61-6 [9916919.001]
  • [Cites] J Pathol. 1999 Apr;187(5):563-6 [10398122.001]
  • [Cites] Cancer Metastasis Rev. 1998-1999;17(4):391-9 [10453283.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1462-8 [15619204.001]
  • [Cites] J Histochem Cytochem. 2001 Feb;49(2):271-8 [11156695.001]
  • (PMID = 19002168.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ G0501019; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / RNA, Small Interfering; 0 / TEAD1 protein, human; 0 / Transcription Factors; EC 2.3.2.27 / Proto-Oncogene Proteins c-cbl; EC 6.3.2.- / CBL protein, human
  • [Other-IDs] NLM/ PMC2600693
  •  go-up   go-down


38. Chawla AJ, Tan TY, Tan GJ: Basal cell adenomas of the parotid gland: CT scan features. Eur J Radiol; 2006 May;58(2):260-5
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenomas of the parotid gland: CT scan features.
  • Basal cell adenoma (BCA) is a rare tumor of the parotid gland, and except for a few case reports, the imaging features of this pathological entity are not well described.
  • In all cases, the tumor appeared as a round or oval, sharply marginated mass.
  • The latter two patterns have not been previously described in BCA or other parotid tumors, and may therefore aid in distinguishing BCA from other benign parotid neoplasms on CT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16414228.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


39. Seethala RR, LiVolsi VA, Zhang PJ, Pasha TL, Baloch ZW: Comparison of p63 and p73 expression in benign and malignant salivary gland lesions. Head Neck; 2005 Aug;27(8):696-702
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of p63 and p73 expression in benign and malignant salivary gland lesions.
  • BACKGROUND: The p63 and p73 genes are members of the p53 family and play an important role in stem cell identity and cellular differentiation and are expressed in basal and myoepithelial cells.
  • In this study, we examined the expression of p63 and p73 in 50 various benign salivary gland lesions and 45 malignant salivary gland tumors.
  • RESULTS: In benign lesions, p63 and p73 nuclear reactivity was seen in 46 (92%) of 50 and 47 (94%) of 50 cases, respectively.
  • Also, p73 was found in tumors with minimal basal/myoepithelial differentiation.
  • CONCLUSIONS: Hence, p63 and p73 expression is retained in both benign and malignant salivary gland tumors with basaloid or myoepithelial differentiation.
  • [MeSH-minor] Biomarkers, Tumor. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Transcription Factors. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley Periodicals, Inc.
  • (PMID = 16021638.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  •  go-up   go-down


40. Ali TZ, Epstein JI: Basal cell carcinoma of the prostate: a clinicopathologic study of 29 cases. Am J Surg Pathol; 2007 May;31(5):697-705
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the prostate: a clinicopathologic study of 29 cases.
  • We studied 29 cases of basal cell carcinoma of the prostate including what others call adenoid cystic carcinoma of the prostate.
  • Other patterns included: basal cell hyperplasialike in 9 cases (32%); small tubules occasionally lined by a hyaline rim in 9 cases (32%), with 4 of these cases also demonstrating intermingling cords of cells; and large solid nests in 8 cases (28.5%), 5 of which had central necrosis.
  • Infiltration around benign glands was seen in 10 (36%) cases, with predominantly small nests and AC-P.
  • Perineural and vascular invasion was seen in 2 basal cell carcinomas with large basaloid nests.
  • Basal cell markers (HMWCK, p63) either:.
  • Basal cell carcinomas are rare tumors with a broad morphologic spectrum.
  • The most common morphology among those with an aggressive behavior is large solid nests more often with central necrosis, high Ki67%, and less staining with basal cell markers.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biopsy, Needle. Combined Modality Therapy. Humans. Male. Middle Aged. Mitosis. Neoplasm Recurrence, Local. Retrospective Studies. Transurethral Resection of Prostate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460452.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


41. Mahmoodi M, Asad H, Salim S, Kantor G, Minimo C: Anti-cytokeratin 20 staining of Merkel cells helps differentiate basaloid proliferations overlying dermatofibromas from basal cell carcinoma. J Cutan Pathol; 2005 Aug;32(7):491-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-cytokeratin 20 staining of Merkel cells helps differentiate basaloid proliferations overlying dermatofibromas from basal cell carcinoma.
  • BACKGROUND: Basaloid epidermal proliferations (BEP), morphologically resembling basal cell carcinoma (BCC), have been described overlying dermatofibromas.
  • Anti-CK20 staining of Merkel cells helps differentiate basaloid proliferations overlying dermatofibromas from basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Histiocytoma, Benign Fibrous / diagnosis. Intermediate Filament Proteins / analysis. Merkel Cells / pathology. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cell Count. Cell Proliferation. Diagnosis, Differential. Epidermis / chemistry. Epidermis / pathology. Female. Humans. Immunoenzyme Techniques. Infant, Newborn. Keratin-20. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008693.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / Keratin-20
  •  go-up   go-down


42. Segura S, Puig S, Carrera C, Palou J, Malvehy J: Dendritic cells in pigmented basal cell carcinoma: a relevant finding by reflectance-mode confocal microscopy. Arch Dermatol; 2007 Jul;143(7):883-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cells in pigmented basal cell carcinoma: a relevant finding by reflectance-mode confocal microscopy.
  • A few studies of RCM on basal cell carcinoma (BCC) have provided specific diagnostic criteria, but large studies on pigmented basal cell carcinoma are lacking.
  • Proliferation of large dendritic-shaped cells within a melanocytic tumor has been associated with the diagnosis of melanoma by RCM.
  • Benign melanocytes and Langerhans cells may populate BCC according to previous histological studies.
  • OBSERVATIONS: Reflectance-mode confocal microscopy revealed highly refractive dendritic structures within tumor nests that correlated with the presence of melanocytes within the tumor by immunochemical analysis.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Dendritic Cells / cytology. Skin Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638732.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


43. Kawahara A, Harada H, Akiba J, Yokoyama T, Kage M: Fine-needle aspiration cytology of basal cell adenoma of the parotid gland: characteristic cytological features and diagnostic pitfalls. Diagn Cytopathol; 2007 Feb;35(2):85-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration cytology of basal cell adenoma of the parotid gland: characteristic cytological features and diagnostic pitfalls.
  • We retrospectively studied the cytological features of aspiration cytology in 12 cases of basal cell adenoma (BCA) and 5 cases mistakenly diagnosed as BCA.
  • The characteristic cytological features of solid type BCA were three-dimensional clusters in 71%, sharp-angle small clusters in 86%, basement membrane- like material in 71%, and cell crush in 86%.
  • In contrast, 3 of the 5 cystic type BCA cases showed inadequate cellular components or no basaloid tumor cells, and the cytological diagnosis of BCA could not be determined.
  • In the 5 cases misdiagnosed as BCA, there were 2 cases of pleomorphic adenoma, 2 cases of benign lymphoepithelial cyst, and 1 case of basal cell adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17230571.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Katona TM, Ravis SM, Perkins SM, Moores WB, Billings SD: Expression of androgen receptor by fibroepithelioma of Pinkus: evidence supporting classification as a basal cell carcinoma variant? Am J Dermatopathol; 2007 Feb;29(1):7-12
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of androgen receptor by fibroepithelioma of Pinkus: evidence supporting classification as a basal cell carcinoma variant?
  • The classification of fibroepithelioma of Pinkus as basal cell carcinoma or trichoblastoma remains controversial.
  • Immunohistochemical stains for androgen receptor may be useful in differentiating basal cell carcinoma from trichoepithelioma or trichoblastoma.
  • We studied androgen receptor expression in 13 fibroepitheliomas of Pinkus, 11 basal cell carcinomas, 12 trichoepitheliomas, and 3 trichoblastomas.
  • Androgen receptor expression was present in 77% (10/13) of fibroepitheliomas of Pinkus, 73% (8/11) of basal cell carcinomas, 17% (2/12) of trichoepitheliomas, and 0% (0/3) of trichoblastomas.
  • Androgen receptor expression was significantly higher in fibroepitheliomas of Pinkus compared with trichoepitheliomas and trichoblastomas (P = .0007), but not basal cell carcinoma (P = 1.00).
  • Tumor-associated Merkel cells, a feature of benign follicular tumors, was identified by cytokeratin 20 stains.
  • Merkel cells were identified in 85% (11/13) of fibroepitheliomas of Pinkus, 27% (3/11) of basal cell carcinoma cases, and 73% (11/15) of benign follicular tumors.
  • Cytokeratin 20 expression was significantly higher in fibroepithelioma of Pinkus and benign follicular tumors compared with basal cell carcinomas (P = 0.0111 and P = 0.025, respectively).
  • Similar to basal cell carcinomas, fibroepitheliomas of Pinkus express androgen receptors, potentially supporting classification as a basal cell carcinoma.
  • Conversely, fibroepithelioma of Pinkus demonstrates retention of Merkel cells, a feature of benign follicular tumors.
  • [MeSH-major] Carcinoma, Basal Cell / classification. Carcinoma, Basal Cell / metabolism. Neoplasms, Fibroepithelial / classification. Neoplasms, Fibroepithelial / metabolism. Receptors, Androgen / metabolism. Skin Neoplasms / classification. Skin Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Biopsy. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Genetic Variation / genetics. Hair Follicle / metabolism. Hair Follicle / pathology. Humans. Keratin-20 / genetics. Keratin-20 / metabolism. Merkel Cells / metabolism. Merkel Cells / pathology. Skin / metabolism. Skin / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Dermatopathol. 2007 Oct;29(5):494 [17890926.001]
  • (PMID = 17284955.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Keratin-20; 0 / Receptors, Androgen
  •  go-up   go-down


45. Mancuso M, Gallo D, Leonardi S, Pierdomenico M, Pasquali E, De Stefano I, Rebessi S, Tanori M, Scambia G, Di Majo V, Covelli V, Pazzaglia S, Saran A: Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer. Carcinogenesis; 2009 Feb;30(2):340-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer.
  • Patched1 heterozygous mice (Ptch1(+/-)) are useful for basal cell carcinoma (BCC) studies, being remarkably susceptible to BCC induction by ultraviolet or ionizing radiation.
  • Analogously, skin carcinogenesis-susceptible (Car-S) mice are elective for studies of papilloma and squamous cell carcinoma (SCC) induction.
  • We previously reported a striking effect of gender on BCC induction in Ptch1(+/-) mice, with total resistance of females; likewise, Car-S females show increased skin tumor resistance relative to males.
  • Remarkably, progression of initially benign papillomas to malignant SCC occurred only in ovariectomized Car-S females.
  • We explored the mechanisms underlying tumor progression and report overexpression of estrogen receptor (ER)-alpha, downregulation of ERbeta and upregulation of cyclin D1 in papillomas from ovariectomized Car-S relative to papillomas from CN females.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Estrogens / physiology. Skin Neoplasms / metabolism
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Cyclin D1 / metabolism. Disease Models, Animal. Estrogen Receptor alpha / metabolism. Estrogen Receptor beta / metabolism. Female. Male. Mice. Neoplasms, Radiation-Induced / metabolism. Neoplasms, Radiation-Induced / pathology. Ovariectomy. Papilloma / metabolism. Papilloma / pathology. Receptors, Cell Surface / genetics. Receptors, Cell Surface / metabolism. Ultraviolet Rays


46. Veeresh M, Bavle RM, Vinay KN, Nandakumar H: Basal cell adenoma of the submandibular gland. J Maxillofac Oral Surg; 2010 Sep;9(3):289-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma of the submandibular gland.
  • Basel cell adenoma is a benign epithelial salivary gland tumor that appears to have unique histologic characteristics.
  • Here we report a case of basel cell adenoma of submandibular gland.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22190808.001).
  • [ISSN] 0974-942X
  • [Journal-full-title] Journal of maxillofacial and oral surgery
  • [ISO-abbreviation] J Maxillofac Oral Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3177454
  • [Keywords] NOTNLM ; Adenoma / Basal cells / Submandibular gland
  •  go-up   go-down


47. Zenzmaier C, Untergasser G, Hermann M, Dirnhofer S, Sampson N, Berger P: Dysregulation of Dkk-3 expression in benign and malignant prostatic tissue. Prostate; 2008 Apr 01;68(5):540-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysregulation of Dkk-3 expression in benign and malignant prostatic tissue.
  • Dkk-3 is proposed to function as a secreted tumor suppressor since it is downregulated in a number of cancer cells and prostate cancer tissue and thus may be a promising candidate molecule for therapeutic interference.
  • METHODS: The in situ tissue localization of Dkk-3 protein in normal prostate (NP), benign prostatic hyperplasia (BPH), and prostate carcinoma (PCa) was investigated by immunohistochemistry (IHC)/immunofluorescence.
  • In addition, biological function of Dkk-3 in terms of proliferation and viability was evaluated in primary prostate basal epithelial cells (PrEC), stromal cells (PrSC), and established human PCa cell lines by treatment with recombinant protein or by overexpression.
  • RESULTS: Stimulation with purified recombinant protein and overexpression of Dkk-3 did not significantly alter in vitro cell proliferation in any primary or tumor cell line evaluated.
  • Dkk-3 was expressed in both the basal and secretory epithelium of NP.
  • In BPH expression was restricted to defined basal cells and was absent in tumor cells of high grade PCa.
  • CONCLUSIONS: Our results indicate that Dkk-3 expression in the normal epithelium of the prostate is lost during benign and malignant transformation and differentiation processes.
  • [MeSH-minor] Cell Line. Cell Line, Tumor. Cell Proliferation. Cell Survival. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Cells, Cultured. Endothelium, Vascular / metabolism. Endothelium, Vascular / pathology. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Male. Stromal Cells / metabolism. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18247400.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / FWF/ M 903
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DKK3 protein, human; 0 / Intercellular Signaling Peptides and Proteins
  •  go-up   go-down


48. Garcia FU, Haber MM, Chen X: Prostatic basal cells in the peripheral and transitional zones: zonal variation in morphology and in immunophenotype. Prostate; 2007 Nov 1;67(15):1686-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic basal cells in the peripheral and transitional zones: zonal variation in morphology and in immunophenotype.
  • BACKGROUND: Benign prostatic hyperplasia and prostatic adenocarcinoma exhibit prominent zonal predilections.
  • Basal cells from the transitional zone and from the peripheral zone are postulated to have different underlying biological properties.
  • We studied basal cells in both prostatic zones.
  • TMA sections were stained with a basal cell cocktail (CK 34betaE12 + p63).
  • The immunostaining pattern and the morphology of basal cells were recorded.
  • RESULTS: Triangular-shaped basal cells were highlighted by CK 34betaE12 cytoplasmic and p63 nuclear staining.
  • These basal cells had their long axis oriented perpendicular to the basement membrane and their apex toward the lumen interdigited between secretory luminal cells.
  • This morphology was seen in the majority of peripheral zone benign prostatic glands (92.0%) but only a minority of transitional zone benign prostatic glands (18.0%).
  • Basal cells of the transitional zone showed weak or absent CK 34betaE12 staining in 65.9% of glands while maintaining p63.
  • All glands with high-grade prostatic intraepithelial neoplasia (HGPIN) contained the triangular basal cells.
  • In addition, basal cell clusters were identified in 8.7% of peripheral zone glands and 5.2% of HGPIN glands.
  • CONCLUSIONS: Our results indicate that the basal cell morphology and the basal cell immunophenotype have a zonal variation.
  • The finding of a unique morphology of basal cells and the presence of basal cell clusters in the peripheral zone suggests that the peripheral zone might be the stem/progenitor cell-rich area in the human prostates.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Cell Nucleus / chemistry. Cell Nucleus / pathology. Humans. Image Processing, Computer-Assisted. Immunoenzyme Techniques. Keratins / analysis. Male. Membrane Proteins / analysis. Middle Aged. Neoplastic Stem Cells / chemistry. Neoplastic Stem Cells / pathology. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879949.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CK-34 beta E12; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


49. Serafin AM, Bohm L: Influence of p53 and bcl-2 on chemosensitivity in benign and malignant prostatic cell lines. Urol Oncol; 2005 Mar-Apr;23(2):123-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of p53 and bcl-2 on chemosensitivity in benign and malignant prostatic cell lines.
  • The administration of cancer chemotherapeutic agents results in an increase in the apoptotic cells in the tumor: therefore, it has been assumed that anticancer drugs exhibit their cytotoxic effects via apoptotic signaling pathways.
  • The role of p53 and bax/bcl-2 in drug-induced apoptosis was assessed in six prostate cell lines, 1532T, 1535T, 1542T, 1542N, BPH-1 and LNCaP using TD(50) concentrations of etoposide, vinblastine and estramustine.
  • Cell death was monitored morphologically by fluorescent microscopy, and by flow cytometry (Annexin-V assay).
  • The percentage of cells responding to drug-induced apoptosis was, on average, higher in the tumor cell lines than in the normal cell lines, but showed no correlation with p53 status.
  • Immunoblotting demonstrated that bax and bcl-2 proteins were expressed at a basal level in all cell lines, but did not increase after exposure to TD(50) doses of the three drugs.
  • The results suggest that apoptosis is not a major mechanism of drug-induced cell death in prostate cell lines and appears to be independent of p53 status and bax/bcl-2 expression.
  • [MeSH-minor] Apoptosis / drug effects. Apoptosis / genetics. DNA Damage. Dose-Response Relationship, Drug. Gene Expression Profiling. Humans. Male. Necrosis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15869997.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 35LT29625A / Estramustine; 5V9KLZ54CY / Vinblastine
  •  go-up   go-down


50. Andreadis D, Epivatianos A, Poulopoulos A, Nomikos A, Papazoglou G, Antoniades D, Barbatis C: Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. Oral Oncol; 2006 Jan;42(1):57-65
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours.
  • Archival formalin-fixed, paraffin-embedded sections of 40 benign and 57 malignant salivary gland tumours were retrieved and retrospectively studied immunohistochemically using a polyclonal C-KIT antibody in an Envision/HRP technique.
  • In addition five samples of chronic submandibular sialadenitis, five normal minor salivary glands and parotid or submandibular gland tissue adjacent to benign tumour were also studied.
  • C-KIT expression was observed in cases of adenoid cystic, acinic cell polymorphous low grade, epithelial-myoepithelial, carcinosarcoma and basal cell adenocarcinomas, as in luminal cells of pleomorphic adenomas, in serous acinar and only in intercalated and a small number of striated ductal cells of inflammatory salivary gland tissue, whereas normal salivary lobules were generally negative except a weak positivity of intercalated cells.
  • Contrary to other reports, this study suggests that, C-KIT protein does not appear to be an exclusively specific marker for benign or malignant salivary gland neoplasms, but may be useful in differential diagnosis of adenoid cystic carcinoma from polymorphous low grade adenocarcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Adenoid Cystic / chemistry. Proto-Oncogene Proteins c-kit / analysis. Salivary Gland Neoplasms / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140564.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


51. Nakabayashi M, Shomori K, Kiya S, Shiomi T, Nosaka K, Ito H: Tubular-trabecular type Basal cell adenoma of the parotid gland: a patient report. Yonago Acta Med; 2010 Sep;53(3):65-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubular-trabecular type Basal cell adenoma of the parotid gland: a patient report.
  • Basal cell adenoma (BCA) is an uncommon benign salivary gland neoplasm that includes isomorphic basaloid cells.
  • The present patient demonstrated a few tumor nests in the fibrous capsule, and her tumor was larger than usual.
  • Histopathologically, the tumor was characterized by multiple duct-like structures and tubular-trabecular masses composed of small isomorphic cells with hyperchromatic, round nuclei and an eosinophilic cytoplasm.
  • It was difficult to determine whether the ductal structures noted in the tumor capsule were invasive.
  • By immunohistochemistry, tumor cells of the tubular nests were positive for cytokeratin 7 and that the outer cells of tubular nests were positive for alpha smooth muscle actin (αSMA) and calponin.
  • Tumor cells were immuno-negative for S-100 protein and glial fibrillary acidic protein.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24031120.001).
  • [ISSN] 0513-5710
  • [Journal-full-title] Yonago acta medica
  • [ISO-abbreviation] Yonago Acta Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC3763784
  • [Keywords] NOTNLM ; basal cell adenoma / immunohistochemistry / parotid gland
  •  go-up   go-down


52. Khamis ZI, Iczkowski KA, Sahab ZJ, Sang QX: Protein profiling of isolated leukocytes, myofibroblasts, epithelial, Basal, and endothelial cells from normal, hyperplastic, cancerous, and inflammatory human prostate tissues. J Cancer; 2010;1:70-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein profiling of isolated leukocytes, myofibroblasts, epithelial, Basal, and endothelial cells from normal, hyperplastic, cancerous, and inflammatory human prostate tissues.
  • For cells to become invasive, the prostate gland must undergo degradation of the basement membrane and disruption of the basal cell layer underneath the luminal epithelia.
  • Although the roles of proteinases in breaking down the basement membrane have been well-studied, little is known about the factors that induce basal cell layer disruption, degeneration, and its eventual disappearance in invasive cancer.
  • It is hypothesized that microenvironmental factors may affect the degradation of the basal cell layer, which if protected may prevent tumor progression and invasion.
  • In this study, we have revealed differential protein expression patterns between epithelial and stromal cells isolated from different prostate pathologies and identified several important epithelial and stromal proteins that may contribute to inflammation and malignant transformation of human benign prostate tissues to cancerous tissues using matrix-assisted laser desorption ionization time-of-flight mass spectrometry and proteomics methods.
  • Cellular retinoic acid-binding protein 2 was downregulated in basal cells of benign prostate.
  • Proto-oncogene Wnt-3 was downregulated in endothelial cells of prostatitis tissue and tyrosine phosphatase non receptor type 1 was only found in normal and benign endothelial cells.
  • Further validation of these proteins may generate new strategies for the prevention of basal cell layer disruption and subsequent cancer invasion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20842227.001).
  • [ISSN] 1837-9664
  • [Journal-full-title] Journal of Cancer
  • [ISO-abbreviation] J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Other-IDs] NLM/ PMC2938068
  • [Keywords] NOTNLM ; Prostate cancer / inflammation / magnetic bead cell separation / protein biomarkers / tumor microenvironment / tumorigenesis
  •  go-up   go-down


53. Haskell HD, Haynes HA, McKee PH, Redston M, Granter SR, Lazar AJ: Basal cell carcinoma with matrical differentiation: a case study with analysis of beta-catenin. J Cutan Pathol; 2005 Mar;32(3):245-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with matrical differentiation: a case study with analysis of beta-catenin.
  • Matrical differentiation in basal cell carcinoma (BCC) is rare.
  • Immunohistochemical and molecular methods are used to differentiate this lesion from benign or malignant forms of pilomatrixoma. differentiation: a case study with analysis of beta-catenin.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Cell Transformation, Neoplastic. Cytoskeletal Proteins / analysis. Skin Neoplasms / pathology. Trans-Activators / analysis
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Hair Diseases / diagnosis. Humans. Immunohistochemistry. Male. Mohs Surgery. Pilomatrixoma / diagnosis. beta Catenin

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701088.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / P30AR042689
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / Trans-Activators; 0 / beta Catenin
  •  go-up   go-down


54. Sedghizadeh PP, Wong D, Shuler CF, Linz V, Kalmar JR, Allen CM: Multifocal calcifying epithelial odontogenic tumor. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Aug;104(2):e30-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal calcifying epithelial odontogenic tumor.
  • The calcifying epithelial odontogenic tumor (CEOT), or Pindborg tumor, is a rare and benign odontogenic neoplasm that affects the jaw.
  • For example, multiple odontogenic keratocysts are the most common feature of the inherited condition known as nevoid basal cell carcinoma syndrome.
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Rare Diseases

  • Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17630096.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Trepp R, Padberg BC, Varga Z, Cathomas R, Inauen R, Reinhart WH: Extensive extranodal metastases of basal-like breast cancer with predominant myoepithelial spindle cell differentiation. Pathol Res Pract; 2010 May 15;206(5):334-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive extranodal metastases of basal-like breast cancer with predominant myoepithelial spindle cell differentiation.
  • These include multifocal myoepitheliomatosis, the rare mixed tumor or pleomorphic adenoma, adenoid cystic carcinoma, adenomyoepithelioma and myoepithelial carcinoma (malignant myoepithelioma).
  • All these tumors are benign and/or of low-grade malignancy, with the exception of malignant myoepithelioma.
  • The presented case of a breast carcinoma with dominant myoepithelial/spindle cell differentiation in a 58-year-old woman is an excellent example to document the highly aggressive biological behavior of this tumor phenotype.
  • Despite an extensive chemotherapy and radiotherapy, the tumor was rapidly progressive, forming a finally exulcerating local tumor relapse and widespread metastases to the myocardium, lungs, liver, kidneys and skin.
  • Similarities in morphology and biological behavior compared to patients with "triple-negative" (hormone receptor and Her2) monophasic sarcomatoid carcinomas and pure spindle cell sarcomas are discussed.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic / pathology. Fatal Outcome. Female. Humans. Middle Aged


56. Hatta N, Hirano T, Kimura T, Hashimoto K, Mehregan DR, Ansai S, Takehara K, Takata M: Molecular diagnosis of basal cell carcinoma and other basaloid cell neoplasms of the skin by the quantification of Gli1 transcript levels. J Cutan Pathol; 2005 Feb;32(2):131-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnosis of basal cell carcinoma and other basaloid cell neoplasms of the skin by the quantification of Gli1 transcript levels.
  • BACKGROUND: Distinguishing basal cell carcinoma (BCC) from other benign and malignant skin tumors is sometimes a difficult task for the pathologists.
  • The tumors included BCC (21), squamous cell carcinoma (13), seborrheic keratoses (8), trichoepithelioma (5), eccrine poroma/porocarcinoma (4), and sebaceous epithelioma/carcinoma (2).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / diagnosis. Oncogene Proteins / metabolism. Skin Neoplasms / diagnosis. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606671.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Gli protein; 0 / Oncogene Proteins; 0 / RNA, Messenger; 0 / Trans-Activators; 0 / Transcription Factors
  •  go-up   go-down


57. Ali F, Brown A, Gottwald L, Thomas J: Basal cell carcinoma with matrical differentiation in a transplant patient: a case report and review of the literature. J Cutan Pathol; 2005 Jul;32(6):445-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with matrical differentiation in a transplant patient: a case report and review of the literature.
  • BACKGROUND: Shadow cells, characterized by basaloid squamous cells with a distinct well-defined border and a central unstained area as a shadow of lost nuclei, are characteristic of pilomatricoma, a distinct neoplasm of hair matrix differentiation.
  • The presence of shadow cells within tumor islands composed of follicular germinative cells of an otherwise classic basal cell carcinoma (BCC) has been considered as a distinct diagnostic category of BCC with matrical differentiation.
  • In these areas, the tumor nodules were connected to the epidermis, whereas in others, it extended deep into the reticular dermis to the subcutaneous fat junction.
  • Elsewhere, the majority of the tumor contained a population of shadow cells, similar to those in pilomatricoma, with basaloid-appearing matrical cells in the periphery.
  • Areas of cystic degeneration were present throughout the tumor.
  • CONCLUSION: BCC with matrical differentiation is a distinct pathologic entity and a rare subtype of BCC featuring shadow and matrical cells, typically seen in pilomatricoma, a benign hair matrix neoplasm.
  • This tumor has not yet been reported in an immunosuppressed transplant patient.
  • [MeSH-major] Carcinoma, Basal Cell / immunology. Carcinoma, Basal Cell / pathology. Heart Transplantation. Immunocompromised Host. Skin Neoplasms / immunology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15953381.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


58. Abbas NF, Labib El-Sharkawy S, Abbas EA, Abdel Monem El-Shaer M: Immunohistochemical study of p53 and angiogenesis in benign and preneoplastic oral lesions and oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar;103(3):385-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical study of p53 and angiogenesis in benign and preneoplastic oral lesions and oral squamous cell carcinoma.
  • Angiogenesis also has been demonstrated to be associated with tumor progression, aggressiveness, and metastases.
  • This study aimed to investigate-in normal oral epithelium, hyperplasia, dysplasia, and invasive oral squamous cell carcinoma-the prevalence of p53 protein immunoreactivity and of angiogenesis, and to determine the correlation between them.
  • STUDY DESIGN: The study was performed on tissue sections of hyperplasia (n = 14), dysplasia (n = 10), and invasive squamous cell carcinoma (n = 21).
  • RESULTS: This study showed that p53 protein was confined to the basal cell layer in normal oral mucosa and in the hyperplastic group.
  • In the dysplastic group, it was expressed in the basal and suprabasal layer, whereas in invasive carcinoma, it was detected in central and peripheral regions.
  • The percentage of p53-positive cells was evaluated, and statistically significant differences were found between normal oral mucosa and severe dysplasia, between normal mucosa and invasive carcinoma, and between mild and severe dysplasia. p53 expression showed no significant correlation with tumor grading.
  • Angiogenesis was assessed using the endothelial cell marker von Willebrand's factor.
  • [MeSH-major] Carcinoma, Squamous Cell / chemistry. Mouth Neoplasms / chemistry. Neovascularization, Pathologic. Precancerous Conditions / chemistry. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Analysis of Variance. Biomarkers, Tumor. Cell Transformation, Neoplastic. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Mouth Mucosa / chemistry. Mouth Mucosa / pathology. Mutation. Prognosis. Statistics, Nonparametric. von Willebrand Factor / analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17321451.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; 0 / von Willebrand Factor
  •  go-up   go-down


59. Ozolek JA, Barnes EL, Hunt JL: Basal/myoepithelial cells in chronic sinusitis, respiratory epithelial adenomatoid hamartoma, inverted papilloma, and intestinal-type and nonintestinal-type sinonasal adenocarcinoma: an immunohistochemical study. Arch Pathol Lab Med; 2007 Apr;131(4):530-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal/myoepithelial cells in chronic sinusitis, respiratory epithelial adenomatoid hamartoma, inverted papilloma, and intestinal-type and nonintestinal-type sinonasal adenocarcinoma: an immunohistochemical study.
  • One feature of malignant glandular lesions is loss of the basal/myoepithelial layer.
  • The immunophenotype of the basal/myoepithelial layer has not been fully examined in benign glandular lesions of the sinonasal tract.
  • OBJECTIVE: To examine benign and malignant glandular lesions in the sinonasal tract for the immunophenotype of basal/myoepithelial cells, proliferation index, and cytokeratin and intestinal differentiation profiles.
  • RESULTS: Basal/myoepithelial cells in CS and REAH were positive for p63 and 34betaE12 but negative for SMA, S100 protein, and calponin.
  • Sixty percent of morphologic ITACs expressed CDX-2.
  • CONCLUSIONS: Basal/myoepithelial cells in CS and REAH should be considered basal and not myoepithelial cells.
  • In benign lesions, proliferative activity is limited to the compartments with p63 staining.
  • [MeSH-minor] Actins / metabolism. Biomarkers, Tumor / analysis. Calcium-Binding Proteins / metabolism. Cell Proliferation. Chronic Disease. Diagnosis, Differential. Epithelial Cells / pathology. Female. Homeodomain Proteins / metabolism. Humans. Immunohistochemistry. Immunophenotyping. Ki-67 Antigen / metabolism. Male. Membrane Proteins / metabolism. Microfilament Proteins / metabolism. Middle Aged. S100 Proteins / metabolism. Trans-Activators / metabolism

  • MedlinePlus Health Information. consumer health - Sinusitis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17425380.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Calcium-Binding Proteins; 0 / Homeodomain Proteins; 0 / Ki-67 Antigen; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / S100 Proteins; 0 / Trans-Activators; 0 / calponin; 156560-97-3 / Cdx-2-3 protein; 68238-35-7 / Keratins
  •  go-up   go-down


60. Skroza N, Panetta C, Schwartz RA, Balzani A, Rota C, Buccheri EM, Alfano C, Innocenzi D: Giant meta-typical carcinoma: an unusual tumor. Acta Dermatovenerol Croat; 2006;14(1):46-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant meta-typical carcinoma: an unusual tumor.
  • Meta-typical carcinoma (MTC) or basosquamous carcinoma is a remarkable malignancy with features of both basal and squamous cell carcinoma.
  • It is typically located on the back and face, often with clinical features of basal cell carcinoma but tending to be more aggressive with enhanced prospects of lymph node or distant metastases.
  • Our report describes a huge neglected MTC of the back of ten-year duration, a giant ulcero-vegetative tumor measuring 20 x 25 cm.
  • Histologic examination of specimens from the margins and periphery revealed aspects of both basal and squamous cell carcinoma, while the ulcerated center showed sclerotic tissue without tumor.
  • The MTC we describe exhibited benign biologic behavior.
  • This may have been related to an intense inflammatory host response with elimination of neoplastic tissue and consequent local sclerosis evident in the central tumor-free portion.
  • This central tumor regression is to our knowledge a unique finding in MTC.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16603102.001).
  • [ISSN] 1330-027X
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


61. Garraway IP, Sun W, Tran CP, Perner S, Zhang B, Goldstein AS, Hahm SA, Haider M, Head CS, Reiter RE, Rubin MA, Witte ON: Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate; 2010 Apr 1;70(5):491-501
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo.
  • They may be targets for tumor initiation, so characterization of these cells may have therapeutic implications.
  • Subpopulations of prostate epithelial cells were isolated by cell sorting and interrogated for sphere-forming activity.
  • RESULTS: Prostate tissue specimens were heterogeneous, containing both benign and malignant (Gleason 3-5) glands.
  • A basal phenotype (CD44+CD49f+CK5+p63+CK8-AR-PSA-) was observed among sphere-forming cells.
  • Subpopulations of prostate cells expressing tumor-associated calcium signal transducer 2 (Trop2), CD44, and CD49f preferentially formed spheres.
  • In vivo implantation of sphere-forming cells and rUGSM regenerated tubular structures containing discreet basal and luminal layers.
  • The TMPRSS-ERG fusion was absent in prostaspheres derived from fusion-positive tumor tissue, suggesting a survival/growth advantage of benign prostate epithelial cells.
  • CONCLUSION: Human prostate sphere-forming cells self-renew, have tissue regeneration capability, and represent a subpopulation of basal cells.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • [Cites] Br J Cancer. 2000 Feb;82(4):990-7 [10732776.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20882-7 [19088204.001]
  • [Cites] Br J Cancer. 2001 Aug 17;85(4):590-9 [11506501.001]
  • [Cites] J Cell Sci. 2001 Nov;114(Pt 21):3865-72 [11719553.001]
  • [Cites] J Pathol. 2001 Dec;195(5):563-70 [11745692.001]
  • [Cites] Mol Cancer Res. 2002 Dec;1(2):113-21 [12496358.001]
  • [Cites] Genes Dev. 2003 May 15;17(10):1253-70 [12756227.001]
  • [Cites] Brain Res. 2003 Dec 12;993(1-2):18-29 [14642827.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3029-35 [14701873.001]
  • [Cites] J Cell Sci. 2004 Jul 15;117(Pt 16):3539-45 [15226377.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7274-82 [15378087.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):209-14 [15368472.001]
  • [Cites] J Neurosci Res. 2004 Oct 15;78(2):215-23 [15378509.001]
  • [Cites] J Steroid Biochem Mol Biol. 1996 Nov;59(3-4):243-50 [9010316.001]
  • [Cites] Differentiation. 1998 Jul;63(3):131-40 [9697307.001]
  • [Cites] Hum Pathol. 1998 Sep;29(9):1005-12 [9744319.001]
  • [Cites] J Cell Physiol. 1999 Nov;181(2):304-11 [10497309.001]
  • [Cites] Acta Biochim Pol. 2005;52(2):353-8 [15990920.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9269-79 [16230388.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Nat Med. 2006 Mar;12(3):296-300 [16520777.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1880-5 [16574858.001]
  • [Cites] Cancer Cell. 2006 May;9(5):367-78 [16697957.001]
  • [Cites] Eur J Cancer. 2006 Jun;42(9):1213-8 [16632344.001]
  • [Cites] Brain Res. 2006 Aug 30;1107(1):82-96 [16859652.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8598-607 [16951173.001]
  • [Cites] N Engl J Med. 2006 Sep 21;355(12):1253-61 [16990388.001]
  • [Cites] Nat Methods. 2006 Oct;3(10):801-6 [16990812.001]
  • [Cites] Mol Carcinog. 2007 Jan;46(1):1-14 [16921491.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):181-6 [17185413.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4807-15 [17510410.001]
  • [Cites] Prostate. 2007 Sep 15;67(13):1384-96 [17639507.001]
  • [Cites] Dev Biol. 2007 Dec 1;312(1):396-406 [17976567.001]
  • [Cites] Cancer Res. 2008 Dec 1;68(23):9703-11 [19047148.001]
  • [Cites] Prostate. 2001 Feb 1;46(2):142-53 [11170142.001]
  • (PMID = 19938015.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-16042; United States / NIAID NIH HHS / AI / AI-28697; United States / NHGRI NIH HHS / HG / F31 HG000117; United States / NCI NIH HHS / CA / P30 CA016042; United States / NHGRI NIH HHS / HG / HG000117-05; United States / NIAID NIH HHS / AI / P30 AI028697; United States / NHGRI NIH HHS / HG / F31 HG000117-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Antigens, CD44; 0 / CD44 protein, human; 0 / Glycoproteins; 0 / Integrin alpha6; 0 / Oncogene Proteins, Fusion; 0 / Peptides; 0 / TMPRSS2-ERG fusion protein, human
  • [Other-IDs] NLM/ NIHMS187861; NLM/ PMC2885946
  •  go-up   go-down


62. Kammori M, Izumiyama N, Nakamura K, Kurabayashi R, Kashio M, Aida J, Poon SS, Kaminishi M: Telomere metabolism and diagnostic demonstration of telomere measurement in the human esophagus for distinguishing benign from malignant tissue by tissue quantitative fluorescence in situ hybridization. Oncology; 2006;71(5-6):430-6
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomere metabolism and diagnostic demonstration of telomere measurement in the human esophagus for distinguishing benign from malignant tissue by tissue quantitative fluorescence in situ hybridization.
  • OBJECTIVE: We have developed a novel method for evaluating telomere length in four different cell types in non-cancerous and cancerous mucosal tissue from 15 cases of squamous cell carcinoma of the esophagus using tissue quantitative fluorescence in situ hybridization (Q-FISH).
  • We hypothesized that the very rapid cell proliferation observed in esophageal squamous cell carcinomas might accelerate the telomere shortening and chromosomal instability associated with carcinogenesis.
  • METHODS: Tissue Q-FISH and the telomere to centromere intensity ratio (TCR) were used to compare telomere shortening in tissue sections taken from esophageal squamous cell carcinomas and adjacent non-cancerous esophageal tissues.
  • RESULTS: The peak percentage of TCR was <1 for esophageal squamous carcinoma cells and >1 for the non-cancerous esophageal cell types.
  • Basal layer cells had the longest telomeres in comparison with prickle, cancer, and stromal cells, and strongly expressed hTERT, cytokeratin 14 and CD49f, but not MIB-1.
  • CONCLUSION: These results suggest the presence of stem cells in the basal layer of the esophagus.
  • Esophageal squamous cell carcinomas also display anaphase bridges, evidencing chromosomal instability.
  • In conclusion, our TCR method can be used to distinguish between benign and malignant tissue in esophageal lesions.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Esophageal Neoplasms / diagnosis. Esophagus / pathology. In Situ Hybridization, Fluorescence / methods. Telomere / genetics
  • [MeSH-minor] Aged. Anaphase / genetics. Biomarkers, Tumor / biosynthesis. Centromere / pathology. Chromosomal Instability / genetics. Humans. Male. Middle Aged. Stem Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 17878747.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


63. Ali TZ, Epstein JI: False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells. Am J Surg Pathol; 2008 Dec;32(12):1890-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells.
  • We compared p63 and HMWCK immunostaining to check their specificity for basal cell identification.
  • The size of the tumor on needle biopsy ranged from 0.5 to 6.0 mm (mean 1 mm) and on the 2 TURP cases consisted of 44 and 68 cancer glands, respectively.
  • The number of tumor cells positive for HMWCK in each of the needle biopsy cases ranged from 3 to 48 (mean 13 cells), whereas on the 2 TURP cases 26 and 10 cells were labeled with HMWCK.
  • In 3 of 4 cases, p63 labeled 1, 1, and 2 tumor cells, respectively.
  • To assess whether overstaining was a factor, we evaluated the intensity of HMWCK staining in the basal cells of the benign glands, which was moderate in 6 and strong in 16 cases.
  • The cytoplasm of benign secretory cells showed focal weak (n=3), diffuse weak (n=1), and focal moderate (n=2) staining for HMWCK.
  • HMWCK labeling of prostate cancer cells is uncommon and does not seem to be solely attributable to overstaining. p63 is a more specific marker for basal cells than HMWCK, with less labeling of tumor cells.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / analysis. Keratins / biosynthesis. Membrane Proteins / biosynthesis. Prostatic Neoplasms / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18813120.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


64. McPherson SJ, Hussain S, Balanathan P, Hedwards SL, Niranjan B, Grant M, Chandrasiri UP, Toivanen R, Wang Y, Taylor RA, Risbridger GP: Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc Natl Acad Sci U S A; 2010 Feb 16;107(7):3123-8
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated.
  • Prostate cancer (PCa) and benign prostatic hyperplasia (BPH) are androgen-dependent diseases commonly treated by inhibiting androgen action.
  • ERbeta agonist induces apoptosis in prostatic stromal, luminal and castrate-resistant basal epithelial cells of estrogen-deficient aromatase knock-out mice.
  • These data provide evidence of the beneficial effects of ERbeta agonist on epithelium and stroma of BPH, as well as androgen-independent tumor cells implicated in recurrent disease.
  • [MeSH-major] Apoptosis / physiology. Estrogen Receptor beta / metabolism. Hyperplasia / metabolism. Prostate / pathology. Prostatic Neoplasms / metabolism. Tumor Necrosis Factor-alpha / metabolism
  • [MeSH-minor] Analysis of Variance. Androgens / metabolism. Animals. Cell Line, Tumor. Gene Expression Profiling. Humans. Immunohistochemistry. Male. Mice. Mice, Knockout

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Biol. 2001 Jan 15;229(2):432-42 [11150243.001]
  • [Cites] Nature. 2008 Dec 11;456(7223):804-8 [18946470.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):79-92 [11438457.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6089-97 [11507058.001]
  • [Cites] J Cell Sci. 2001 Nov;114(Pt 21):3865-72 [11719553.001]
  • [Cites] Trends Endocrinol Metab. 2002 May-Jun;13(4):163-8 [11943560.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13589-94 [12370428.001]
  • [Cites] J Mol Endocrinol. 2004 Feb;32(1):55-67 [14765992.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9375-80 [15187231.001]
  • [Cites] Mol Endocrinol. 2004 Jul;18(7):1599-609 [15105439.001]
  • [Cites] Ernst Schering Res Found Workshop. 2004;(46):47-62 [15248504.001]
  • [Cites] J Cell Sci. 2004 Jul 15;117(Pt 16):3539-45 [15226377.001]
  • [Cites] Prostate. 1987;11(3):229-42 [3684783.001]
  • [Cites] J Androl. 1991 Nov-Dec;12(6):376-80 [1722793.001]
  • [Cites] Differentiation. 1996 Jul;60(4):219-27 [8765052.001]
  • [Cites] Br J Urol. 1997 Apr;79 Suppl 2:18-26 [9126066.001]
  • [Cites] Eur J Immunol. 1997 Oct;27(10):2600-9 [9368616.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6965-70 [9618522.001]
  • [Cites] J Urol. 1999 Jan;161(1):169-72 [10037391.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Nov;26(3):185-91 [10502315.001]
  • [Cites] Cancer Biol Ther. 2005 Feb;4(2):139-63 [15725726.001]
  • [Cites] Prostate. 2005 Jul 1;64(2):149-59 [15678503.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Biochem Pharmacol. 2006 May 14;71(10):1459-69 [16554039.001]
  • [Cites] Mol Cell Biochem. 2006 Jul;287(1-2):137-45 [16633737.001]
  • [Cites] J Urol. 2006 Sep;176(3):965-70; discussion 970-1 [16890670.001]
  • [Cites] Endocrinology. 2007 Feb;148(2):566-74 [17068134.001]
  • [Cites] Nat Rev Cancer. 2007 Aug;7(8):621-7 [17611544.001]
  • [Cites] Cardiovasc Res. 2008 Mar 1;77(4):774-81 [18056768.001]
  • [Cites] FASEB J. 2008 May;22(5):1512-20 [18055862.001]
  • [Cites] J Natl Cancer Inst. 2008 Jun 4;100(11):815-25 [18505969.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6407-15 [18676866.001]
  • [Cites] Differentiation. 2008 Jul;76(6):660-70 [18557760.001]
  • [Cites] Bone. 2008 Nov;43(5):849-55 [18708178.001]
  • [Cites] Cancer Res. 2008 Dec 1;68(23):9703-11 [19047148.001]
  • [Cites] Endocrinology. 2001 Jun;142(6):2458-67 [11356695.001]
  • (PMID = 20133657.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Estrogen Receptor beta; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC2840300
  •  go-up   go-down


65. Peschos D, Damala C, Stefanou D, Tsanou E, Assimakopoulos D, Vougiouklakis T, Charalabopoulos K, Agnantis NJ: Expression of matrix metalloproteinase-9 (gelatinase B) in benign, premalignant and malignant laryngeal lesions. Histol Histopathol; 2006 06;21(6):603-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of matrix metalloproteinase-9 (gelatinase B) in benign, premalignant and malignant laryngeal lesions.
  • They are involved in basement membrane disruption, stroma and blood vessel penetration, metastasis and more recently there is evidence that they participate in tumor growth and angiogenic events.
  • Matrix metalloproteinase 2 and 9 (MMP 2 and 9) belong to the gelatinases, a subgroup of MMPs, and have the capacity to degrade the triple helix type IV collagen of basal lamina of the basement membrane.
  • With the present study, we tried to demonstrate the expression of MMP-9 immunohistochemically, comparatively in benign, premalignant and malignant lesions of the larynx.
  • We studied 154 laryngeal lesions including 55 squamous cell carcinomas, 8 in situ carcinomas, 54 cases of dysplasia (of low and intermediate grade), 13 papillomas and 24 cases of keratosis.
  • Overexpression of MMP 9 was observed in 74.4% and 50% in invasive and in situ squamous cell carcinomas respectively.
  • In dysplastic cases, in papillomas and in keratoses the percentage of overexpression was 62.9%, 61.53% and 54.16% respectively and the expression of MMP-9 was significantly higher in invasive squamous cell carcinomas compared to dysplasias (p=0.000004).
  • The MMP-9 expression was related neither to survival nor to the other available clinicopathological parameters (tumor size, grade, clinical stage, lymph node status and patient age).
  • [MeSH-minor] Carcinoma in Situ / chemistry. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Disease Progression. Female. Humans. Immunohistochemistry. Keratosis / metabolism. Keratosis / pathology. Laryngeal Diseases / metabolism. Laryngeal Diseases / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Papilloma / chemistry. Papilloma / metabolism. Papilloma / pathology. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16528670.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


66. Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ: Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res; 2005 Aug 1;65(15):6640-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.
  • Putative prostate stem cells and prostate tumor stem cells in benign and malignant human prostate tissue, in primary human prostate xenografts, and in the transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model of prostate cancer, are defined by expression of breast cancer resistance protein (BCRP), a marker of pluripotent hematopoietic, muscle, and neural stem cells, and by an absence of androgen receptor (AR) protein.
  • Inhibition of BCRP-mediated efflux of dihydrotestosterone by novobiocin or fumitremorgin C in a rat prostate progenitor cell line that expresses BCRP and AR mRNAs, but minimal AR protein, results in stabilization and nuclear translocation of AR protein, providing a mechanism for lack of AR protein in BCRP-expressing stem cells.
  • In both benign and malignant human prostate tissue, the rare epithelial cells that express BCRP and lack AR protein are localized in the basal cell compartment, survive androgen deprivation, and maintain proliferative potential in the hypoxic, androgen-deprived prostate.
  • Putative prostate tumor stem cells that express BCRP but not AR protein in TRAMP are the source of a BCRP-negative and AR-negative, Foxa2- and SV40Tag-expressing, transit amplifying compartment that progresses to the poorly differentiated carcinomas that arise rapidly after castration.
  • Therefore, BCRP expression isolates prostate stem/tumor stem cells from the prostate tissue microenvironment through constitutive efflux of androgen, protecting the putative tumor stem cells from androgen deprivation, hypoxia, or adjuvant chemotherapy, and providing the nidus for recurrent prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NOVOBIOCIN .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061644.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA84296; United States / NCI NIH HHS / CA / P01 CA077739; United States / NCI NIH HHS / CA / CA77739; United States / NCI NIH HHS / CA / CA64851; United States / NIEHS NIH HHS / ES / ES07017; United States / NCI NIH HHS / CA / CA64865
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / Androgens; 0 / Indoles; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Receptors, Androgen; 17EC19951N / Novobiocin; CW5S8OP3VO / tryptoquivaline
  •  go-up   go-down


67. Garnier B, Simon E, Dumont T, Sellal S, Stricker M, Chassagne JF: [Goal cell carcinoma: really a low malignancy tumor?]. Rev Stomatol Chir Maxillofac; 2005 Feb;106(1):16-21
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Goal cell carcinoma: really a low malignancy tumor?].
  • [Transliterated title] Les carcinomes cutanés basocellulaires méritent-ils leur réputation de tumeurs à faible malignité?
  • Although basal cell carcinoma often presents as a fairly "benign" lesion early in its course, it remains the most frequent malignancy worldwide.
  • We show that advanced basal cell carcinoma can be mutilating or even life threatening depending on location, type of lesion, or pre-existing co-morbidity.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Facial Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Humans. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15798647.001).
  • [ISSN] 0035-1768
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 22
  •  go-up   go-down


68. Morikawa T, Nagata M, Tomita K, Kitamura T, Goto A, Chong JM, Fukayama M: Phyllodes tumor of the prostate with exuberant glandular hyperplasia. Pathol Int; 2006 Mar;56(3):158-61
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumor of the prostate with exuberant glandular hyperplasia.
  • Reported herein is an unusual case of prostatic phyllodes tumor with exuberant glandular hyperplasia that led to misdiagnosis of adenocarcinoma.
  • The tumor was detected in a 52-year-old man who had a 1 year history of dysuria.
  • Histologically, the tumor had an atypical stromal cell proliferation and elongated slit-like glands characteristic of a phyllodes tumor.
  • The tumor was also accompanied by a florid proliferation of small acini, most of which lacked basal cells, a common manifestation of adenocarcinoma in the overall tumor area.
  • The following features of the resected tumor were helpful for concluding that these acini were benign: lack of cytological anaplasia in spite of structural atypia, presence of scattered basal cells confirmed by immunohistochemistry (high-molecular-weight cytokeratin), and histological transition from these acini to apparently benign slit-like glands.
  • The final diagnosis was then made as 'phyllodes tumor of the prostate with exuberant glandular hyperplasia'.
  • Atypical stromal cells might provide a clue for the recognition of this rare tumor at initial diagnosis by needle biopsy.
  • [MeSH-major] Biopsy, Needle. Diagnostic Errors. Phyllodes Tumor / pathology. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497250.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


69. Mogensen M, Joergensen TM, Nürnberg BM, Morsy HA, Thomsen JB, Thrane L, Jemec GB: Assessment of optical coherence tomography imaging in the diagnosis of non-melanoma skin cancer and benign lesions versus normal skin: observer-blinded evaluation by dermatologists and pathologists. Dermatol Surg; 2009 Jun;35(6):965-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of optical coherence tomography imaging in the diagnosis of non-melanoma skin cancer and benign lesions versus normal skin: observer-blinded evaluation by dermatologists and pathologists.
  • OBJECTIVES: To describe OCT features in NMSC such as actinic keratosis (AK) and basal cell carcinoma (BCC) and in benign lesions and to assess the diagnostic accuracy of OCT in differentiating NMSC from benign lesions and normal skin.
  • Observer-blinded evaluation of OCT images from 64 BCCs, 1 baso-squamous carcinoma, 39 AKs, two malignant melanomas, nine benign lesions, and 105 OCT images from perilesional skin was performed; 50 OCT images of NMSC and 50 PS-OCT images of normal skin were evaluated twice.
  • OCT diagnosis is less accurate than clinical diagnosis, but high accuracy in distinguishing lesions from normal skin, crucial for delineating tumor borders, was obtained.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19397661.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


70. Louis SN, Wang L, Chow L, Rezmann LA, Imamura K, MacGregor DP, Casely D, Catt KJ, Frauman AG, Louis WJ: Appearance of angiotensin II expression in non-basal epithelial cells is an early feature of malignant change in human prostate. Cancer Detect Prev; 2007;31(5):391-5
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appearance of angiotensin II expression in non-basal epithelial cells is an early feature of malignant change in human prostate.
  • METHODS: Using immunohistochemistry, we examined Ang II expression in prostate cancer (Gleason grades 2-5), benign prostatic hyperplasia (BPH), and high-grade prostatic intraepithelial neoplasia (HGPIN).
  • RESULTS: Ang II was present in proliferating neoplastic cells in HGPIN, in malignant cells in all grades of prostate cancer examined, in basal but not luminal epithelial cells in BPH, and in the cytoplasm of LNCaP, DU145, and PC3 prostate cancer cells.
  • CONCLUSIONS: The data establishes the presence of Ang II in pre-malignant and malignant prostate cells, suggests Ang II staining in non-basal epithelial cells is an early sign of malignant change, and supports suggestions that HGPIN and malignant prostate cells both arise from transformed basal cells.
  • Using immunohistochemistry we examined Ang II expression in proliferative disorders of the prostate and concluded that Ang II staining in non-basal epithelial cells is evidence of early malignant change.
  • [MeSH-major] Angiotensin II / biosynthesis. Cell Transformation, Neoplastic / metabolism. Epithelial Cells / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Blotting, Western. Humans. Immunohistochemistry. Male

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18031950.001).
  • [ISSN] 1525-1500
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 11128-99-7 / Angiotensin II
  •  go-up   go-down


71. Johnykutty S, Tang P, Zhao H, Hicks DG, Yeh S, Wang X: Dual expression of alpha-tocopherol-associated protein and estrogen receptor in normal/benign human breast luminal cells and the downregulation of alpha-tocopherol-associated protein in estrogen-receptor-positive breast carcinomas. Mod Pathol; 2009 Jun;22(6):770-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual expression of alpha-tocopherol-associated protein and estrogen receptor in normal/benign human breast luminal cells and the downregulation of alpha-tocopherol-associated protein in estrogen-receptor-positive breast carcinomas.
  • The hormonal carcinogenesis of breast cancer involves hormone-driven cell proliferation and genetic alterations, including oncogene activation and suppressor gene inactivation.
  • Our previous studies identified a gene, namely alpha-tocopherol-associated protein, which is preferentially expressed in normal/benign breast and prostate tissue, but its expression is downregulated in breast and prostate carcinomas.
  • To further examine its function in hormone-induced carcinogenesis, we examined if there is an association between alpha-tocopherol-associated protein and estrogen-receptor expression in normal/benign breast tissue and in human breast carcinomas.
  • We found that alpha-tocopherol-associated protein is coexpressed with estrogen receptor in the luminal cells of normal/benign breast tissue in a scattered manner by immunohistochemical staining of consecutive tissue sections of 20 cases, whereas alpha-tocopherol-associated protein expression is downregulated in 46% (45 of 98) of estrogen-receptor/progesterone-receptor-positive, so-called luminal type A or B human breast carcinoma.
  • This is similar to the association of alpha-tocopherol-associated protein and androgen receptor expression in normal/benign prostate and prostate carcinomas.
  • In contrast,alpha-tocopherol-associated protein expression is mostly negative in basal, Her2 and triple-negative nonbasal subtypes of high-grade breast carcinomas.
  • These findings are consistent with alpha-tocopherol-associated protein acting as an antiproliferative factor in estrogen-receptor-positive luminal cells in normal/benign breast tissue. alpha-Tocopherol-associated protein downregulation may have triggered hormonal carcinogenesis in at least some of the breast carcinomas, providing further, albeit indirect evidence to support a role for vitamin E in breast cancer prevention.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Down-Regulation. Female. Gene Expression. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19305383.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Lipoproteins; 0 / Receptors, Estrogen; 0 / SEC14L2 protein, human; 0 / Trans-Activators
  •  go-up   go-down


72. Lin SY, Liu WY, Chen WC, Chen RH: Secondary hypertension due to a renin-secreting juxtaglomerular cell tumor. J Formos Med Assoc; 2010 Mar;109(3):237-40
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary hypertension due to a renin-secreting juxtaglomerular cell tumor.
  • A juxtaglomerular cell tumor (JCT) is a rare, renin-secreting tumor of the kidney and can cause hypertension.
  • JCT is pathologically benign, and resection of the tumor is curative for hypertension.
  • Laboratory studies showed increased basal plasma renin activity, but normal serum aldosterone level.

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Formosan Medical Association & Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20434032.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] EC 3.4.23.15 / Renin
  •  go-up   go-down


73. Savage K, Lambros MB, Robertson D, Jones RL, Jones C, Mackay A, James M, Hornick JL, Pereira EM, Milanezi F, Fletcher CD, Schmitt FC, Ashworth A, Reis-Filho JS: Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res; 2007 Jan 1;13(1):90-101
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis.
  • PURPOSE: The distribution and significance of caveolin 1 (CAV1) expression in different breast cell types and role in breast carcinogenesis remain poorly understood.
  • Both tumor-suppressive and oncogenic roles have been proposed for this protein.
  • The aims of this study were to characterize the distribution of CAV1 in normal breast, benign breast lesions, breast cancer precursors, and metaplastic breast carcinomas; to assess the prognostic significance of CAV1 expression in invasive breast carcinomas; and to define whether CAV1 gene amplification is the underlying genetic mechanism driving CAV1 overexpression in breast carcinomas.
  • CAV1 expression was immunohistochemically analyzed in benign lesions, breast cancer precursors, and metaplastic breast carcinomas and in a cohort of 245 invasive breast carcinomas from patients treated with surgery followed by anthracycline-based chemotherapy.
  • In the later cohort, CAV1 expression was significantly associated with 'basal-like' immunophenotype and with shorter disease-free and overall survival on univariate analysis.
  • CONCLUSIONS: The concurrent CAV1 amplification and overexpression call into question its tumor-suppressive effects in basal-like breast carcinomas.
  • [MeSH-minor] Cell Line, Tumor. Female. Humans. Immunophenotyping. Microscopy, Fluorescence. Microscopy, Immunoelectron. Neoplasm Invasiveness. Neoplasm Metastasis. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17200343.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caveolin 1
  •  go-up   go-down


74. Fischer S, Breuninger H, Metzler G, Hoffmann J: Microcystic adnexal carcinoma: an often misdiagnosed, locally aggressive growing skin tumor. J Craniofac Surg; 2005 Jan;16(1):53-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic adnexal carcinoma: an often misdiagnosed, locally aggressive growing skin tumor.
  • Recently it has been proposed that MAC is an apocrine tumor.
  • In 1982, Goldstein and colleagues first reported MAC to be a distinct histologic entity characterized by a combination of keratinous cysts in the upper dermis, islands and strands of small basaloid, benign-appearing keratinocytes or squamous cells in the deeper dermis within a dense desmoplastic stroma, and areas of ductular differentiation.
  • The authors report the case of a 78-year-old woman in whom a diagnosis of MAC was made when a tumor on the right cheek recurred for the second time.
  • Previous histopathologic diagnoses were squamous cell carcinoma and desmoplastic trichoepithelioma.
  • Local recurrences of the tumor occurred, despite histographic surgery because in hematoxylin and eosin stains, small islands of the deceptively benign-appearing small basaloid cells of MAC were not recognized as tumor cells.
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasms, Basal Cell / pathology

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15699645.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Li LJ, Li Y, Wen YM, Liu H, Zhao HW: Clinical analysis of salivary gland tumor cases in West China in past 50 years. Oral Oncol; 2008 Feb;44(2):187-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical analysis of salivary gland tumor cases in West China in past 50 years.
  • In our study, 3461 cases of salivary gland tumor treated between 1955 and 2002 at West China Stomatology Hospital of Sichuan University were retrospectively analyzed, and compared with the previous reports.
  • Measures such as age, tumor location, tumor histological type, and the nature of the growth (benign or malignant) were recorded at the same time.
  • The findings are as follows: the average ages of salivary gland tumor patients were 41.38 years for the benign cases and 45.20 for the malignant ones; the male:female ratio was 0.
  • 99:1 in the benign cases and 1.34:1 in the malignant ones; primary tumors were mostly in the parotid gland, palate and submandibular gland in sequence.
  • Pleomorphic adenoma was the most frequent benign tumor followed by Warthin's tumor and basal cell adenoma, whereas mucoepidermoid carcinoma, adenoid cystic carcinoma and adenocarcinoma not otherwise specified were the most frequent malignant tumors.
  • The male:female ratio of malignant tumors was higher than that of benign ones.
  • Pleomorphic adenoma and mucoepidermoid carcinoma were the most frequent benign and malignant tumors, respectively.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Oral Oncol. 2011 Sep;47(9):929-30
  • (PMID = 17418612.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


76. Cajaiba MM, Bale AE, Alvarez-Franco M, McNamara J, Reyes-Múgica M: Rhabdomyosarcoma, Wilms tumor, and deletion of the patched gene in Gorlin syndrome. Nat Clin Pract Oncol; 2006 Oct;3(10):575-80
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma, Wilms tumor, and deletion of the patched gene in Gorlin syndrome.
  • The patient underwent surgical removal of both neoplasms, which were diagnosed as a rhabdomyosarcoma and a Wilms tumor.
  • Seven years later, she presented with macroglossia and a benign mandibular cyst.
  • DIAGNOSIS: Gorlin syndrome with synchronous rhabdomyosarcoma and Wilms tumor.
  • MANAGEMENT: Left nephrectomy, excision of paravesical tumor, excision of mandibular cysts, chemotherapy, and radiotherapy.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology. Kidney Neoplasms / surgery. Rhabdomyosarcoma / surgery. Wilms Tumor / surgery
  • [MeSH-minor] Bone Cysts / complications. Child, Preschool. Female. Humans. Macroglossia / etiology. Mandible. Receptors, Cell Surface / genetics

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17019435.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


77. Ferreira M, Fujiwara H, Morita K, Watt FM: An activating beta1 integrin mutation increases the conversion of benign to malignant skin tumors. Cancer Res; 2009 Feb 15;69(4):1334-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An activating beta1 integrin mutation increases the conversion of benign to malignant skin tumors.
  • One of these, T188Ibeta1, was identified as a heterozygous mutation in a poorly differentiated squamous cell carcinoma (SCC) and shown to activate extracellular matrix adhesion and inhibit keratinocyte differentiation in vitro.
  • To study its contribution to tumor development, we overexpressed the mutant or wild-type (WT) human beta1 subunit in the basal layer of mouse epidermis using the keratin 14 promoter.
  • The transgenic integrins were expressed at the cell surface and were functional, with the T188Ibeta1 subunit promoting cell spreading to a greater extent than WTbeta1.
  • Epidermal proliferation and differentiation were unaffected and no expansion of the stem cell compartment was detected.
  • These observations establish that the expression of a genetic variant in the I-like domain of beta1 integrins does not affect normal epidermal homeostasis, but increases tumor susceptibility and influences tumor type.
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Cell Adhesion. Cell Differentiation. Cell Division. Female. Flow Cytometry. Heterozygote Detection. Humans. In Situ Hybridization. Keratinocytes / cytology. Keratinocytes / physiology. Mice. Mice, Transgenic. Polymerase Chain Reaction. Polymorphism, Genetic. Skin / cytology


78. Arwert EN, Lal R, Quist S, Rosewell I, van Rooijen N, Watt FM: Tumor formation initiated by nondividing epidermal cells via an inflammatory infiltrate. Proc Natl Acad Sci U S A; 2010 Nov 16;107(46):19903-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor formation initiated by nondividing epidermal cells via an inflammatory infiltrate.
  • In mammalian epidermis, integrin expression is normally confined to the basal proliferative layer that contains stem cells.
  • In transgenic mice, expression of activated MAPK kinase 1 (MEK1) in the suprabasal, nondividing, differentiated cell layers (InvEE transgenics) results in epidermal hyperproliferation and skin inflammation.
  • We now demonstrate that wounding induces benign tumors (papillomas and keratoacanthomas) in InvEE mice.
  • By generating chimeras between InvEE mice and mice that lack the MEK1 transgene, we demonstrate that differentiating, nondividing cells that express MEK1 stimulate adjacent transgene-negative cells to divide and become incorporated into the tumor mass.
  • Dexamethasone treatment inhibits tumor formation, suggesting that inflammation is involved.
  • InvEE skin and tumors express high levels of IL1α; treatment with an IL1 receptor antagonist delays tumor onset and reduces incidence.
  • Depletion of γδ T cells and macrophages also reduces tumor incidence.
  • In contrast, our studies show that differentiated epidermal cells can initiate tumor formation without reacquiring the ability to divide and that they do so by triggering an inflammatory infiltrate.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2001 Aug;108(4):527-36 [11518726.001]
  • [Cites] Dev Cell. 2010 Jun 15;18(6):884-901 [20627072.001]
  • [Cites] EMBO J. 2002 Aug 1;21(15):3919-26 [12145193.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 Nov;43(11):3473-9 [12407158.001]
  • [Cites] Dermatol Surg. 2002 Oct;28(10):954-8 [12410683.001]
  • [Cites] Bone Marrow Transplant. 2002 Dec;30(12):843-9 [12476275.001]
  • [Cites] J Immunol. 2003 Jun 1;170(11):5697-703 [12759452.001]
  • [Cites] J Exp Med. 2003 Sep 1;198(5):747-55 [12953094.001]
  • [Cites] J Invest Dermatol. 2004 Sep;123(3):503-15 [15304090.001]
  • [Cites] J Clin Invest. 1986 Jun;77(6):1857-63 [3486886.001]
  • [Cites] Cancer Res. 1989 Nov 15;49(22):6419-24 [2553256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jan;87(2):538-42 [2105486.001]
  • [Cites] Cell. 1990 Sep 7;62(5):863-74 [1975515.001]
  • [Cites] Immunology. 1992 Feb;75(2):293-8 [1532379.001]
  • [Cites] Cancer Immunol Immunother. 1995 Jun;40(6):358-66 [7627992.001]
  • [Cites] Exp Dermatol. 1997 Feb;6(1):22-8 [9067703.001]
  • [Cites] J Immunol. 1997 Nov 15;159(10):5084-8 [9366437.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):211-7 [15766659.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3577-85 [15867351.001]
  • [Cites] Arch Ophthalmol. 2005 Jul;123(7):957-63 [16009838.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):175-83 [16498442.001]
  • [Cites] J Clin Invest. 2006 Aug;116(8):2094-104 [16886058.001]
  • [Cites] J Leukoc Biol. 2007 Jan;81(1):1-5 [17032697.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):2916-21 [17409394.001]
  • [Cites] Dev Cell. 2007 Apr;12(4):615-29 [17419998.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Apr;66(1):1-9 [17913510.001]
  • [Cites] Immunol Rev. 2008 Apr;222:155-61 [18364000.001]
  • [Cites] Nature. 2008 May 15;453(7193):314-21 [18480812.001]
  • [Cites] J Exp Med. 2008 Jun 9;205(6):1261-8 [18490490.001]
  • [Cites] Nature. 2008 Jul 24;454(7203):436-44 [18650914.001]
  • [Cites] Methods Mol Biol. 2009;481:141-54 [19096804.001]
  • [Cites] Burns. 2009 May;35(3):318-26 [18951718.001]
  • [Cites] Semin Immunol. 2009 Jun;21(3):110-20 [19369094.001]
  • [Cites] J Cell Sci. 2009 Jul 15;122(Pt 14):2473-80 [19549682.001]
  • [Cites] Nat Med. 2009 Sep;15(9):1010-2 [19734877.001]
  • [Cites] Cancer Metastasis Rev. 2010 Jun;29(2):317-29 [20422276.001]
  • [Cites] Infect Immun. 2001 Dec;69(12):7213-23 [11705890.001]
  • (PMID = 21041641.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-1alpha; 0 / Receptors, Antigen, T-Cell, gamma-delta
  • [Other-IDs] NLM/ PMC2993377
  •  go-up   go-down


79. Pino M, Galleguillos C, Torres M, Sovino H, Fuentes A, Boric MA, Johnson MC: Association between MMP1 and MMP9 activities and ICAM1 cleavage induced by tumor necrosis factor in stromal cell cultures from eutopic endometria of women with endometriosis. Reproduction; 2009 Nov;138(5):837-47
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between MMP1 and MMP9 activities and ICAM1 cleavage induced by tumor necrosis factor in stromal cell cultures from eutopic endometria of women with endometriosis.
  • Endometriosis is a benign gynecological pathology in which immune system deregulation may play a role in its initiation and progression.
  • In endometriotic lesions, intercellular adhesion molecule-1 (ICAM1) is released from the cell membrane by proteolytic cleavage of its extracellular domain, a process that coincides with increased expression and proteolytic activity of metalloproteinases such as MMP1 and MMP9.
  • The objective of our study was to investigate the association between MMP1 and MMP9 activities and ICAM1 cleavage mediated by tumor necrosis factor (TNF) in eutopic endometrial stromal cells from women with and without (control) endometriosis during culture.
  • Under basal conditions, proMMP9 dimer and MMP9 were higher in endometriosis cell cultures.
  • In stromal cultures derived from control women and those with endometriosis, TNF augmented the intracellular proMMP1 (1.2-fold in control stromal cells) and ICAM1 (1.4- and 1.9-fold), greatly increased MMP1 and proMMP9 levels, and the sICAM1 concentration (2.3- and 4.3-fold) in their media compared with basal levels.
  • The combination of TNF and MMP9 increased the sICAM1 concentration 14-fold in the endometriosis cell media, whereas GM6001 inhibited the stimulatory effect of TNF in both cell cultures.
  • [MeSH-major] Endometriosis / pathology. Endometrium / pathology. Intercellular Adhesion Molecule-1 / metabolism. Matrix Metalloproteinase 1 / metabolism. Matrix Metalloproteinase 9 / metabolism. Stromal Cells / drug effects. Tumor Necrosis Factor-alpha / pharmacology. Uterine Diseases / pathology
  • [MeSH-minor] Adult. Case-Control Studies. Cells, Cultured. Enzyme Activation / drug effects. Enzyme Activation / genetics. Enzyme Activation / physiology. Female. Humans. Primary Cell Culture. Protein Processing, Post-Translational / drug effects

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661147.001).
  • [ISSN] 1741-7899
  • [Journal-full-title] Reproduction (Cambridge, England)
  • [ISO-abbreviation] Reproduction
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 126547-89-5 / Intercellular Adhesion Molecule-1; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


80. DeVilliers P, Liu H, Suggs C, Simmons D, Daly B, Zhang S, Raubenheimer E, Larsson A, Wright T: Calretinin expression in the differential diagnosis of human ameloblastoma and keratocystic odontogenic tumor. Am J Surg Pathol; 2008 Feb;32(2):256-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calretinin expression in the differential diagnosis of human ameloblastoma and keratocystic odontogenic tumor.
  • Ameloblastoma is a benign, locally aggressive epithelial odontogenic tumor that has the potential to become malignant and produce metastasis to distant sites such as lungs and kidneys.
  • The histologic presentation can be, in some instances, mistaken for keratocystic odontogenic tumor (KCOT) (formerly known as odontogenic keratocyst).
  • Gene expression profiling of ameloblastomas showed CALB2 expressed in the basal cell layer of columnar cells resembling preameloblasts, in all 5 of the ameloblastomas evaluated.
  • [MeSH-major] Ameloblastoma / diagnosis. Biomarkers, Tumor / metabolism. Jaw Neoplasms / diagnosis. Odontogenic Cysts / diagnosis. Odontogenic Tumors / diagnosis. S100 Calcium Binding Protein G / metabolism
  • [MeSH-minor] Calbindin 2. Diagnosis, Differential. Gene Expression. Gene Expression Profiling. Humans. RNA, Messenger / metabolism. RNA, Neoplasm / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223328.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / DE016079
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / S100 Calcium Binding Protein G
  •  go-up   go-down


81. Kazakov DV, Schaller J, Vanecek T, Kacerovska D, Michal M: Brooke-Spiegler syndrome: report of a case with a novel mutation in the CYLD gene and different types of somatic mutations in benign and malignant tumors. J Cutan Pathol; 2010 Aug;37(8):886-90
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brooke-Spiegler syndrome: report of a case with a novel mutation in the CYLD gene and different types of somatic mutations in benign and malignant tumors.
  • The available histopathological material included 24 trichoepitheliomas, 2 large nodular basal cell carcinomas (BCCs), 2 spiradenomas, 1 spiradenocylindroma and 1 trichoblastoma composed of large and small nodules with prominent clear cell differentiation.
  • Whereas one of the two BCCs manifested a conventional morphology, the second neoplasm additionally showed foci with high grade cytological features characterized by marked pleomorphism and numerous mitotic figures.
  • [MeSH-major] Adenoma / genetics. Carcinoma, Adenoid Cystic / genetics. Carcinoma, Basal Cell / genetics. Carcinoma, Skin Appendage / genetics. Facial Neoplasms / genetics. Skin Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Brooke-Spiegler syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20132422.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CYLD protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


82. Pacchioni D, Volante M, Casetta G, Sapino A, Marchiò C, Bussolati G: Myxoid renal tumor with myoepithelial differentiation mimicking a salivary gland pleomorphic adenoma: description of a case. Am J Surg Pathol; 2007 Apr;31(4):632-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myxoid renal tumor with myoepithelial differentiation mimicking a salivary gland pleomorphic adenoma: description of a case.
  • We herein report an unusual case of a low-grade myxoid renal epithelial neoplasm, with peculiar and previously unreported morphologic and immunohistochemical features.
  • These were lined by 2 different epithelial cell types, flat and elongated basal cells and cuboidal to spindle shaped eosinophilic luminal cells, with low-grade nuclear features and a few small nucleoli.
  • The immunohistochemical profile interestingly confirmed the myoepithelial differentiation of the basal epithelial layer, as demonstrated by the coexpression of several myoepithelial markers such as p63, caldesmon, calponin, smooth muscle actin, and S-100, together with epithelial markers such as low and high-molecular weight cytokeratins.
  • The tumor proved benign at follow-up.
  • A definitive classification and histogenetic interpretation of this previously unreported tumor type awaits description of further cases showing similar features which, perhaps, as it may happen, went so far unnoticed.
  • [MeSH-minor] Adenoma, Pleomorphic / pathology. Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Salivary Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Salivary gland adenoma, pleomorphic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414112.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


83. Mhawech-Fauceglia P, Herrmann FR, Bshara W, Odunsi K, Terracciano L, Sauter G, Cheney RT, Groth J, Penetrante R, Mhawech-Fauceglia P: Friend leukaemia integration-1 expression in malignant and benign tumours: a multiple tumour tissue microarray analysis using polyclonal antibody. J Clin Pathol; 2007 Jun;60(6):694-700

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Friend leukaemia integration-1 expression in malignant and benign tumours: a multiple tumour tissue microarray analysis using polyclonal antibody.
  • BACKGROUND: Friend leukaemia integration-1 (FLI-1) antibody is a useful marker for Ewing's sarcoma/primitive neuroectodermal tumour (EWS/PNET) and vascular tumours.
  • However, it is also expressed in subsets of lymphoblastic lymphoma, Merkel cell carcinoma (MCC) and desmoplastic small round cell tumour (DSRCT).
  • AIM: To determine expression of FLI-1 in various benign and malignant neoplasms, by immunohistochemical analysis on 4323 tumours using multiple tumour microarrays, as well as on whole sections.
  • RESULTS: FLI-1 was expressed in 46/62 EWS/PNETs, 2/3 olfactory neuroblastomas, 7/102 small cell carcinomas of the lung, 10/34 MCCs, 1/14 rhabdomyosarcoma, 19/132 non-Hodgkin's lymphomas, 2/3 DSRCTs, and in 53/74 benign and malignant vascular tumours.
  • In addition, 27/508 squamous cell carcinomas, 19/837 adenocarcinomas, 10/400 urothelial bladder cancers, 1/40 basal cell carcinomas, 3/29 liposarcomas, 1/40 glioblastoma multiforme and 9/29 medullar carcinomas of the breast expressed FLI-1.
  • Finally, the sensitivity and specificity of FLI-1 to distinguish EWS/PNET from other small round cell tumours (SRCTs) were 74.2% and 91.6%, respectively.
  • This finding should be kept in mind, especially when using FLI-1 as a marker for finding the primary origin of poorly differentiated metastatic tumour.
  • Finally, despite the expression of FLI-1 in numerous malignancies, it is still considered to be highly sensitive and specific in distinguishing EWS/PNET from other tumour types in general and from other SRCTs in particular.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Neoplasms / metabolism. Proto-Oncogene Protein c-fli-1 / metabolism
  • [MeSH-minor] Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / metabolism. Diagnosis, Differential. Humans. Immunoenzyme Techniques. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / metabolism. Neuroectodermal Tumors, Primitive / diagnosis. Neuroectodermal Tumors, Primitive / metabolism. Protein Array Analysis / methods. Sarcoma, Ewing / diagnosis. Sarcoma, Ewing / metabolism. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1061-6 [11474291.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1657-62 [11117787.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5747-54 [11607824.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):320-7 [11859203.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):994-1000 [14608532.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Mod Pathol. 2004 May;17(5):547-52 [15001993.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Jun;12(2):160-5 [15354743.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):721-7 [15491968.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Int J Dev Biol. 1998 May;42(4):561-72 [9694627.001]
  • [Cites] Histopathology. 2005 Jun;46(6):622-34 [15910593.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1025-33 [16006796.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1184-93 [16096408.001]
  • [Cites] Int J Gynecol Pathol. 2006 Apr;25(2):151-4 [16633064.001]
  • [Cites] Semin Diagn Pathol. 2000 Aug;17(3):216-24 [10968707.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Sep;9(3):255-60 [11556754.001]
  • (PMID = 16917000.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Protein c-fli-1
  • [Other-IDs] NLM/ PMC1955051
  •  go-up   go-down


84. Mateus GC, Lanza GH, de Moura PH, Marigo Hde A, Horta MC: Cell proliferation and apoptosis in keratocystic odontogenic tumors. Med Oral Patol Oral Cir Bucal; 2008 Nov;13(11):E697-702
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell proliferation and apoptosis in keratocystic odontogenic tumors.
  • OBJECTIVES: Keratocystic odontogenic tumors (KOTs), also known as odontogenic keratocysts, were recently classified as a benign neoplasia due to the aggressive clinical behavior.
  • Therefore, the aim of this study is to evaluate and compare the proliferation index (PI) and the apoptotic index (AI) of the epithelial lining in sporadic KOTs, KOTs associated with the Nevoid Basal Cell Carcinoma Syndrome (NBCCS KOTs), and dentigerous cysts.
  • The PI was assessed by immunohistochemical detection of the cell proliferation marker Ki-67.
  • In dentigerous cysts, the PI was higher in the basal layer.
  • No difference in the AI was observed between the basal layer and the suprabasal layer in the three lesions.
  • CONCLUSIONS: The present study demonstrates that the epithelial lining of KOTs shows a distinct pattern of cell proliferation and apoptosis, reflecting its high cell turnover and reinforcing its classification as an odontogenic tumor.
  • [MeSH-major] Apoptosis. Basal Cell Nevus Syndrome / pathology. Cell Proliferation. Mouth Neoplasms / pathology. Odontogenic Tumors / pathology

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18978709.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  •  go-up   go-down


85. Hałoń A, Błazejewska M, Sabri H, Rabczyński J: [Tumors and tumor-like lesions of eyelids collected at Department of Pathological Anatomy, Wroclaw Medical University, between 1946 and 1999]. Klin Oczna; 2005;107(7-9):475-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tumors and tumor-like lesions of eyelids collected at Department of Pathological Anatomy, Wroclaw Medical University, between 1946 and 1999].
  • PURPOSE: To determine the histopathological, epidemiological and clinical characteristics of benign, malignant and tumor-like lesions of the eyelid collected in Department of Pathological Anatomy, Wrocław Medical University.
  • MATERIAL AND METHODS: Department of Pathological Anatomy, Wrocław Medical University, has been collecting data of all tumors and tumor-like lesions of the eye and ocular adnexa diagnosed at the department during the 54-year interval from 1946 through 1999.
  • Benign tumors were the most common lesions (n=1262; 62.2%).
  • Of the 433 malignancies, 314 were basal cell carcinomas (72.5%).
  • Almost 2/3 of all tumor-like lesions in both genders were cysts including atheromas.
  • CONCLUSIONS: Benign eyelid tumors compose the majority of all eyelid lesions.
  • Basal cell carcinoma is the most common malignant eyelid tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16417001.001).
  • [ISSN] 0023-2157
  • [Journal-full-title] Klinika oczna
  • [ISO-abbreviation] Klin Oczna
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


86. Paulino AC, Fowler BZ: Secondary neoplasms after radiotherapy for a childhood solid tumor. Pediatr Hematol Oncol; 2005 Mar;22(2):89-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary neoplasms after radiotherapy for a childhood solid tumor.
  • This study was conducted to determine the outcome of patients who develop a second neoplasm after radiotherapy (RT) for a childhood solid tumor.
  • From 1956 to 1998, 429 children with a malignant solid tumor were treated at a single radiation oncology facility.
  • The medical records and radiotherapy charts were reviewed to determine if the patient developed a secondary neoplasm after treatment for malignancy.
  • Twenty-three (5.4%) patients developed a secondary neoplasm.
  • There were 14 malignant neoplasms in 13 (3.0%) and 14 benign neoplasms in 11 patients (2.6%).
  • The types of initial solid tumors treated with RT were Ewing sarcoma in 6, Wilms tumor in 6, medulloblastoma in 5, neuroblastoma in 3, and other in 3.
  • For the 14 malignant neoplasms, the median time interval from initial tumor to second malignancy was 10.1 years.
  • The 14 second malignant neoplasms (SMN) were osteosarcoma in 3, breast carcinoma in 2, melanoma in 2, malignant fibrous histiocytoma in 1, dermatofibrosarcoma in 1, leiomyosarcoma in 1, mucoepidermoid carcinoma in 1, colon cancer in 1, chronic myelogenous leukemia in 1, and basal cell carcinoma in 1.
  • The 14 benign neoplasms appeared at a median time of 16.9 years and included cervical intraepithelial neoplasia in 3, osteochondroma in 3, thyroid adenoma in 1, duodenal adenoma in 1, lipoma in 1, cherry angioma in 1, uterine leiomyoma in 1, ovarian cystadenofibroma in 1, and giant cell tumor in 1.
  • Only 5 (36%) of the 14 benign tumors occurred in the RT field, with osteochondroma being the most common.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15804994.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


87. Kazakov AA, Grishina EE, Tarantul VZ, Gening LV: Effect of human cell malignancy on activity of DNA polymerase iota. Biochemistry (Mosc); 2010 Jul;75(7):905-11
Hazardous Substances Data Bank. MANGANESE, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of human cell malignancy on activity of DNA polymerase iota.
  • An increased level of mutagenesis, partially caused by imbalanced activities of error prone DNA polymerases, is a key symptom of cell malignancy.
  • To clarify the possible role of incorrect DNA polymerase iota (Pol iota) function in increased frequency of mutations in mammalian cells, the activity of this enzyme in extracts of cells of different mouse organs and human eye (melanoma) and eyelid (basal-cell skin carcinoma) tumor cells was studied.
  • In the presence of Mg2+, the enzyme was active only in cell extracts of mouse testicles and brain, whereas in the presence of Mn2+ the activity of Pol iota was found in all studied normal mouse organs.
  • It was found that in cell extracts of both types of malignant tumors (basal-cell carcinoma and melanoma) Pol iota activity was observed in the presence of either Mn2+ or Mg2+.
  • In the presence of Mn2+ the Pol iota activity in the basal-cell carcinoma exceeded 2.5-fold that in control cells (benign tumors from the same eyelid region).
  • In extracts of melanoma cells in the presence of either cation, the level of the enzyme activity was approximately equal to that in extracts of cells of surrounding tumor-free tissues as well as in eyes removed after traumas.
  • The distinctive feature of tissue malignancy (in basal-cell carcinoma and in melanoma) was the change in DNA synthesis revealed as Mn2+-activated continuation of DNA synthesis after incorrect incorporation of dG opposite dT in the template by Pol iota.
  • Among cell extracts of different normal mouse organs, only those of testicles exhibited a similar feature.
  • This similarity can be explained by cell division blocking that occurs in all normal cells except in testicles and in malignant cells.
  • [MeSH-major] Carcinoma, Basal Cell / enzymology. DNA-Directed DNA Polymerase / metabolism. Eye Neoplasms / enzymology. Lymphoma, B-Cell, Marginal Zone / enzymology. Melanoma / enzymology
  • [MeSH-minor] Animals. Cell Line, Tumor. Enzyme Activation / drug effects. Enzyme Activators / pharmacology. Humans. Magnesium / pharmacology. Manganese / pharmacology. Mice. Mice, Inbred C57BL. Mutation

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20673215.001).
  • [ISSN] 1608-3040
  • [Journal-full-title] Biochemistry. Biokhimii︠a︡
  • [ISO-abbreviation] Biochemistry Mosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Activators; 42Z2K6ZL8P / Manganese; EC 2.7.7.- / DNA polymerase iota; EC 2.7.7.7 / DNA-Directed DNA Polymerase; I38ZP9992A / Magnesium
  •  go-up   go-down


88. Wright NA, Thomas CG, Calame A, Cockerell CJ: Granular cell atypical fibroxanthoma: case report and review of the literature. J Cutan Pathol; 2010 Mar;37(3):380-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell atypical fibroxanthoma: case report and review of the literature.
  • We present a case of granular cell atypical fibroxanthoma of the scalp.
  • The neoplasm occurred as a tender nodule on the frontal scalp of an 82-year-old Caucasian man.
  • The granular cell phenotype has been observed in other cutaneous neoplasms including granular cell tumors, dermatofibromas, dermatofibrosarcoma protuberans, fibrous papules, basal cell carcinomas, leiomyosarcomas, angiosarcomas and primitive polypoid granular cell tumors.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Histiocytoma, Benign Fibrous / pathology. Skin Neoplasms / pathology. Xanthomatosis / pathology
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor. Disease-Free Survival. Humans. Immunohistochemistry. Male. Scalp / metabolism. Scalp / pathology. Scalp / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19341433.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


89. Shao L, Newell B, Quintanilla N: Atypical fibroxanthoma and squamous cell carcinoma of the conjunctiva in xeroderma pigmentosum. Pediatr Dev Pathol; 2007 Mar-Apr;10(2):149-52
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical fibroxanthoma and squamous cell carcinoma of the conjunctiva in xeroderma pigmentosum.
  • The most common tumors reported in patients with XP are squamous cell carcinomas, basal cell carcinomas, and melanomas.
  • Atypical fibroxanthoma (AFX) is a pleomorphic tumor that arises predominantly in the sun-damaged skin of the head and neck regions of the elderly.
  • We describe a unique case of a 6-year-old African American boy with XP who developed an atypical fibroxanthoma and 2 squamous cell carcinomas in the conjunctiva.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Conjunctiva / pathology. Histiocytoma, Benign Fibrous / pathology. Skin Neoplasms / pathology. Xeroderma Pigmentosum / pathology
  • [MeSH-minor] African Americans. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Child, Preschool. Follow-Up Studies. Humans. Immunohistochemistry. Male. Treatment Outcome. Tumor Suppressor Protein p53 / metabolism. Vimentin / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Xeroderma pigmentosum.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378688.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Tumor Suppressor Protein p53; 0 / Vimentin
  •  go-up   go-down


90. Smith EB, Schwartz M, Kawamoto H, You X, Hwang D, Liu H, Scherr DS: Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder. J Urol; 2007 Jun;177(6):2347-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder.
  • It recently showed clinical efficacy against several benign and malignant skin lesions, including actinic keratosis and basal cell carcinoma.
  • MATERIALS AND METHODS: The human and murine J82, T24, TCC-SUP (American Tissue Culture Collection, Manassas, Virginia) and MBT-2 bladder cancer cell lines were cultured in normal culture medium or medium supplemented with imidazoquinoline.
  • Effects on cell viability, apoptosis induction and cytokine production were evaluated.
  • In addition, the effects of imidazoquinoline on in vivo bladder tumor growth were determined via intravesical instillation in an orthotopic bladder tumor model in the mouse.
  • RESULTS: A dose dependent decrease in cell viability was observed in all tumor cell lines treated with imidazoquinoline.
  • In in vivo experiments most mice treated with imidazoquinoline showed only an intense inflammatory response with no evidence of tumor, while control mice showed tumor growth.
  • CONCLUSIONS: Imidazoquinolines have potent direct activity against bladder cancer cells by decreasing cell viability and inducing apoptosis and cytokine production.
  • [MeSH-major] Aminoquinolines / pharmacology. Antineoplastic Agents / pharmacology. Carcinoma / pathology. Cell Line, Tumor / drug effects. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Culture Techniques. Cell Survival / drug effects. Cytokines / metabolism. Disease Models, Animal. Humans. Mice. Toll-Like Receptor 7 / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509356.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Cytokines; 0 / Toll-Like Receptor 7; 99011-02-6 / imiquimod
  •  go-up   go-down


91. Hanker L, Karn T, Ruckhaeberle E, Gaetje R, Solbach C, Schmidt M, Engels K, Holtrich U, Kaufmann M, Rody A: Clinical relevance of the putative stem cell marker p63 in breast cancer. Breast Cancer Res Treat; 2010 Aug;122(3):765-75
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical relevance of the putative stem cell marker p63 in breast cancer.
  • This protein is crucial for the maintenance of a stem cell population in the human epithelium and necessary for the normal development of all epithelial tissues including mammary glands.
  • In normal breast tissue, the p63 seems to be a specific myoepithelial cell marker.
  • P63 expression has been described in highly aggressive ER negative basal-like breast tumors.
  • Tumor samples containing large amounts of benign breast tissue, which will interfere with p63 measurement, were excluded prior to the analysis.
  • [MeSH-major] Breast Neoplasms / metabolism. Neoplastic Stem Cells / metabolism. Receptors, Estrogen / metabolism. Trans-Activators / metabolism. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898932.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


92. Seo PS, Quinn BJ, Khan AA, Zeng L, Takoudis CG, Hanada T, Bolis A, Bolino A, Chishti AH: Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin. Exp Biol Med (Maywood); 2009 Mar;234(3):255-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.
  • Neurofibromatosis type 2 is an inherited disorder characterized by the development of benign and malignant tumors on the auditory nerves and central nervous system with symptoms including hearing loss, poor balance, skin lesions, and cataracts.
  • The p55 is a conserved scaffolding protein with postulated functions in cell shape, hair cell development, and neural patterning of the retina.
  • This finding suggests that the p55-NF2 protein interaction may play a functional role in the regulation of apico-basal polarity and tumor suppression pathways in non-erythroid cells.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2007 Aug 15;16(16):1993-2003 [17584769.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1785(1):32-54 [17980164.001]
  • [Cites] Mol Cell Biol. 2008 Feb;28(4):1274-84 [18086884.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Aug;3(8):586-99 [12154370.001]
  • [Cites] J Biol Chem. 2002 Feb 22;277(8):5699-702 [11741967.001]
  • [Cites] J Biol Chem. 2001 Aug 31;276(35):33093-100 [11432873.001]
  • [Cites] Nat Cell Biol. 2003 Jan;5(1):53-8 [12510194.001]
  • [Cites] J Neurochem. 2003 Jan;84(2):209-21 [12558984.001]
  • [Cites] Sci STKE. 2003 Apr 22;2003(179):RE7 [12709532.001]
  • [Cites] Hum Mol Genet. 2003 Jul 15;12(14):1713-23 [12837694.001]
  • [Cites] Nat Rev Neurosci. 2004 Oct;5(10):771-81 [15378037.001]
  • [Cites] N Engl J Med. 1988 Mar 17;318(11):684-8 [3125435.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6595-9 [1713685.001]
  • [Cites] Cell. 1991 Aug 9;66(3):451-64 [1651169.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Blood. 1993 Aug 15;82(4):1323-7 [8353290.001]
  • [Cites] Cell. 1993 Nov 19;75(4):826 [8242753.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):45-7 [8261460.001]
  • [Cites] J Biol Chem. 1994 Mar 25;269(12):8631-4 [8132590.001]
  • [Cites] J Biol Chem. 1995 Jan 13;270(2):715-9 [7822301.001]
  • [Cites] Genomics. 1996 Jan 15;31(2):223-9 [8824805.001]
  • [Cites] Trends Neurosci. 1996 Sep;19(9):373-7 [8873351.001]
  • [Cites] Nat Genet. 1998 Apr;18(4):354-9 [9537418.001]
  • [Cites] Curr Opin Hematol. 1998 Mar;5(2):116-21 [9570704.001]
  • [Cites] J Cell Biol. 2004 Nov 22;167(4):711-21 [15557122.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10973-8 [16829577.001]
  • [Cites] Can J Neurol Sci. 2006 Nov;33(4):394-402 [17168165.001]
  • (PMID = 19144871.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Grant] Italy / Telethon / / TI/ TCR05002; United States / NHLBI NIH HHS / HL / R01 HL060755; United States / NHLBI NIH HHS / HL / HL60755; United States / NCI NIH HHS / CA / CA 94414; United States / NCI NIH HHS / CA / R01 CA094414
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Blood Proteins; 0 / MPP1 protein, human; 0 / Membrane Proteins; 0 / Neurofibromin 2
  • [Other-IDs] NLM/ NIHMS563000; NLM/ PMC3959803
  •  go-up   go-down


93. Stelkovics E, Korom I, Marczinovits I, Molnar J, Rasky K, Raso E, Ficsor L, Molnar B, Kopper L, Krenacs T: Collagen XVII/BP180 protein expression in squamous cell carcinoma of the skin detected with novel monoclonal antibodies in archived tissues using tissue microarrays and digital microscopy. Appl Immunohistochem Mol Morphol; 2008 Oct;16(5):433-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collagen XVII/BP180 protein expression in squamous cell carcinoma of the skin detected with novel monoclonal antibodies in archived tissues using tissue microarrays and digital microscopy.
  • In this work, highly sensitive monoclonal antibodies 6D1 and 9G2 were produced, characterized, and used for the detection of collagen XVII in a tissue microarray series of archived samples of nonmelanocytic epithelial neoplasias, including 5 verruca vulgaris, 14 seborrheic keratosis, 38 actinic keratosis, 38 basal cell carcinoma (BCC), 15 basosquamous carcinoma, 58 squamous cell carcinoma (SCC), and 9 normal skin.
  • In normal skin and benign epidermal lesions, collagen XVII protein was restricted to basal keratinocytes.
  • However, possibly as a sign of undifferentiated/transformed state, it was widely expressed in SCC showing elevated levels around invasive tumor fronts with some staining in tumor adjacent stroma, endothelium, and histiocytes.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633319.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Autoantigens; 0 / Biomarkers, Tumor; 0 / Non-Fibrillar Collagens; 0 / collagen type XVII
  •  go-up   go-down


94. Bouchelouche K, Alvarez S, Horn T, Nordling J, Bouchelouche P: Human detrusor smooth muscle cells release interleukin-6, interleukin-8, and RANTES in response to proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha. Urology; 2006 Jan;67(1):214-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human detrusor smooth muscle cells release interleukin-6, interleukin-8, and RANTES in response to proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha.
  • In the present study, we extended these studies to include the effect of the proinflammatory cytokines tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta on IL-8, IL-6, and RANTES (regulated on activation, normal T cell expressed and secreted) release by human detrusor smooth muscle cells (HDSMCs) and examined their regulation.
  • METHODS: With ethical approval, detrusor muscle biopsies were obtained from patients with benign noninvasive bladder diseases undergoing control cystoscopy.
  • In nonstimulated HDSMCs, the basal secretion of IL-8, IL-6, and RANTES was detectable.
  • The constitutive and cytokine-stimulated production of chemokines and cytokines suggest that the human detrusor may contribute to mast cell infiltration into the bladder interstitium.
  • The new evidence that HDSMCs secrete immunomodulatory proteins makes the detrusor muscle cell a target for anti-inflammatory therapy.
  • [MeSH-major] Chemokine CCL5 / secretion. Interleukin-1 / physiology. Interleukin-6 / secretion. Interleukin-8 / secretion. Muscle, Smooth / cytology. Muscle, Smooth / secretion. Tumor Necrosis Factor-alpha / physiology. Urinary Bladder / cytology. Urinary Bladder / secretion

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16413378.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chemokine CCL5; 0 / Interleukin-1; 0 / Interleukin-6; 0 / Interleukin-8; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


95. Golod O, Soriano T, Craft N: Palisaded encapsulated neuroma--a classic presentation of a commonly misdiagnosed neural tumor. J Drugs Dermatol; 2005 Jan-Feb;4(1):92-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palisaded encapsulated neuroma--a classic presentation of a commonly misdiagnosed neural tumor.
  • PEN is a previously described, benign cutaneous neural tumour, with a histological appearance between that of a neurofibroma and a schwannoma.
  • Clinically, PEN is most commonly misdiagnosed as a basal cell carcinoma, a nevus, or as a neurofibroma.
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696992.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


96. Lisovsky M, Dresser K, Baker S, Fisher A, Woda B, Banner B, Lauwers GY: Cell polarity protein Lgl2 is lost or aberrantly localized in gastric dysplasia and adenocarcinoma: an immunohistochemical study. Mod Pathol; 2009 Jul;22(7):977-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell polarity protein Lgl2 is lost or aberrantly localized in gastric dysplasia and adenocarcinoma: an immunohistochemical study.
  • Loss of cell polarity, a histological feature of gastric epithelial dysplasia, may be difficult to ascertain, especially in the setting of inflammation or injury.
  • A biomarker of cell polarity could be useful in diagnosis of dysplasia, but has not been reported.
  • The Lethal giant larvae (lgl) gene controls apical-basal polarity of epithelial cells in Drosophila, and has properties of a tumor-suppressor gene.
  • Routinely processed pathology specimens including 94 benign mucosae of digestive organs, in addition to 36 reactive gastropathy, 57 gastric epithelial dysplasia, and 77 gastric adenocarcinomas, were immunostained for Lgl2 protein.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cytoskeletal Proteins / metabolism. Gastric Mucosa / metabolism. Precancerous Conditions / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Cell Polarity. Female. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407852.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Hugl-2 protein, human
  •  go-up   go-down


97. Gluschnaider U, Hidas G, Cojocaru G, Yutkin V, Ben-Neriah Y, Pikarsky E: beta-TrCP inhibition reduces prostate cancer cell growth via upregulation of the aryl hydrocarbon receptor. PLoS One; 2010;5(2):e9060
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] beta-TrCP inhibition reduces prostate cancer cell growth via upregulation of the aryl hydrocarbon receptor.
  • METHODOLOGY/PRINCIPAL FINDINGS: Here we show that beta-TrCP depletion suppresses prostate cancer and identify a relevant growth control mechanism. shRNA targeted against beta-TrCP reduced prostate cancer cell growth and cooperated with androgen ablation in vitro and in vivo.
  • This phenomenon could be ligand independent, as the AhR ligand 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) did not alter prostate cancer cell growth.
  • We detected high AhR expression and activation in basal cells and atrophic epithelial cells of human cancer bearing prostates.
  • AhR expression and activation is also significantly higher in tumor cells compared to benign glandular epithelium.
  • [MeSH-major] Cell Proliferation. Prostatic Neoplasms / genetics. Receptors, Aryl Hydrocarbon / genetics. beta-Transducin Repeat-Containing Proteins / genetics
  • [MeSH-minor] Animals. Blotting, Western. Cell Line. Cell Line, Tumor. Doxycycline / pharmacology. Gene Expression Profiling. Homeodomain Proteins / genetics. Homeodomain Proteins / metabolism. Humans. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Mice, Transgenic. NF-kappa B / metabolism. Oligonucleotide Array Sequence Analysis. Ovariectomy. RNA Interference. Reverse Transcriptase Polymerase Chain Reaction. Tetrachlorodibenzodioxin / pharmacology. Transplantation, Heterologous. Up-Regulation / drug effects

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1998 Nov;72(11):8463-71 [9765382.001]
  • [Cites] Annu Rev Biochem. 1998;67:425-79 [9759494.001]
  • [Cites] Genes Dev. 1999 Mar 1;13(5):505-10 [10072378.001]
  • [Cites] Curr Biol. 1999 Feb 25;9(4):207-10 [10074433.001]
  • [Cites] Curr Opin Chem Biol. 2005 Feb;9(1):51-5 [15701453.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1904-8 [15753389.001]
  • [Cites] Oncogene. 2005 Mar 24;24(13):2271-6 [15735746.001]
  • [Cites] Semin Cell Dev Biol. 2005 Jun;16(3):323-33 [15840441.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 3;102(18):6279-84 [15845771.001]
  • [Cites] Mol Endocrinol. 2005 Jul;19(7):1792-802 [15731171.001]
  • [Cites] Adv Anat Pathol. 2005 Sep;12(5):265-70 [16210922.001]
  • [Cites] J Cell Biochem. 2005 Dec 15;96(6):1174-84 [16211578.001]
  • [Cites] Cell Signal. 2006 Aug;18(8):1309-17 [16303288.001]
  • [Cites] Oncogene. 2006 Jun 8;25(24):3436-44 [16474850.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):19320-6 [16651270.001]
  • [Cites] Biochem Pharmacol. 2006 Aug 14;72(4):393-404 [16545780.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):23060-5 [16757476.001]
  • [Cites] Science. 2006 Oct 20;314(5798):467-71 [17053147.001]
  • [Cites] Proteomics. 2007 Jan;7(1):47-63 [17152098.001]
  • [Cites] Neoplasia. 2006 Dec;8(12):1042-54 [17217622.001]
  • [Cites] Carcinogenesis. 2007 Feb;28(2):497-505 [17052998.001]
  • [Cites] Nature. 2007 Mar 29;446(7135):562-6 [17392787.001]
  • [Cites] Mol Cell Biol. 2007 Jun;27(11):4006-17 [17387146.001]
  • [Cites] FEBS Lett. 2007 Jul 31;581(19):3608-15 [17412325.001]
  • [Cites] Nat Rev Cancer. 2008 Jun;8(6):438-49 [18500245.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6762-9 [18701501.001]
  • [Cites] Prostate. 2008 Dec 1;68(16):1725-33 [18781579.001]
  • [Cites] Cancer Res. 2009 Jan 1;69(1):94-101 [19117991.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):819-27 [19176382.001]
  • [Cites] Int J Cancer. 2009 Apr 15;124(8):1980-9 [19123467.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5085-8 [10537278.001]
  • [Cites] Oncogene. 2000 Apr 13;19(16):1992-2001 [10803460.001]
  • [Cites] Semin Oncol. 2001 Dec;28(6):613-9 [11740819.001]
  • [Cites] Genes Chromosomes Cancer. 2002 May;34(1):9-16 [11921277.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2679-94 [11965541.001]
  • [Cites] Dev Cell. 2003 Jun;4(6):799-812 [12791266.001]
  • [Cites] Arch Toxicol. 2003 Jun;77(6):335-43 [12799773.001]
  • [Cites] Nat Med. 2004 Jan;10(1):33-9 [14702632.001]
  • [Cites] Oncogene. 2004 Mar 15;23(11):2028-36 [15021890.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Jan;88(1):27-36 [15026081.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2523-33 [15059908.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2208-19 [15073094.001]
  • [Cites] Endocr Rev. 2004 Apr;25(2):276-308 [15082523.001]
  • [Cites] Mol Cell Biol. 2004 May;24(9):4038-48 [15082796.001]
  • [Cites] Lancet Oncol. 2004 May;5(5):303-13 [15120667.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 4;96(15):1161-70 [15292388.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(18):8184-94 [15340078.001]
  • [Cites] Urology. 1981 Mar;17(Suppl 3):17-24 [6163242.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):590-4 [9859996.001]
  • (PMID = 20140206.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE19141
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / NF-kappa B; 0 / Receptors, Aryl Hydrocarbon; 0 / beta-Transducin Repeat-Containing Proteins; 128559-51-3 / RAG-1 protein; DO80M48B6O / Tetrachlorodibenzodioxin; N12000U13O / Doxycycline
  • [Other-IDs] NLM/ PMC2816705
  •  go-up   go-down


98. Gil da Costa RM, Rema A, Pires MA, Gärtner F: Two canine Merkel cell tumours: immunoexpression of c-KIT, E-cadherin, beta-catenin and S100 protein. Vet Dermatol; 2010 Apr;21(2):198-201
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two canine Merkel cell tumours: immunoexpression of c-KIT, E-cadherin, beta-catenin and S100 protein.
  • Canine Merkel cell tumours are rare neuroendocrine neoplasms that show a relatively benign biological behaviour when compared with their human counterparts.
  • In both lesions, tumour cells were positive for cytokeratins, CGA, NSE, S100 and c-KIT.
  • These results suggest that the generally benign behaviour of canine Merkel cell tumours, when compared with their human counterparts, may be partly explained by the conservation of important intercellular adhesion molecules such as E-cadherin and beta-catenin.
  • Additionally, expression of S100 but not of the p63 protein suggests that these canine tumours present a trend towards neural, rather than basal, epithelial differentiation and do not readily compare with human Merkel cell tumours.
  • [MeSH-major] Cadherins / metabolism. Carcinoma, Merkel Cell / metabolism. Dog Diseases / diagnosis. Proto-Oncogene Proteins c-kit / metabolism. S100 Proteins / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. Dogs. Female. Gene Expression Regulation, Neoplastic / physiology. Male

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19706008.001).
  • [ISSN] 1365-3164
  • [Journal-full-title] Veterinary dermatology
  • [ISO-abbreviation] Vet. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / S100 Proteins; 0 / beta Catenin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


99. Chakraborty S, Swanson BJ, Bonthu N, Batra SK: Aberrant upregulation of MUC4 mucin expression in cutaneous condyloma acuminatum and squamous cell carcinoma suggests a potential role in the diagnosis and therapy of skin diseases. J Clin Pathol; 2010 Jul;63(7):579-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant upregulation of MUC4 mucin expression in cutaneous condyloma acuminatum and squamous cell carcinoma suggests a potential role in the diagnosis and therapy of skin diseases.
  • METHODS: A total of 330 tissue spots representing the normal skin, and benign and malignant cutaneous diseases, were analysed after staining with the monoclonal antibody to human MUC4 (clone 8G7).
  • RESULTS: While the normal epidermis showed a negative to weak-positive expression of MUC4, its expression was significantly upregulated in squamous cell carcinomas (SCCs) where the intensity of staining correlated negatively with tumour grade and positively with age.
  • Malignant melanoma, basal cell carcinoma and cutaneous cysts were negative.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Genital Warts.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):4-7 [10607349.001]
  • [Cites] Int J Gynecol Pathol. 2009 Mar;28(2):127-33 [19188823.001]
  • [Cites] Dermatol Clin. 2000 Apr;18(2):xv-xxi [10791144.001]
  • [Cites] N Engl J Med. 2001 Mar 29;344(13):975-83 [11274625.001]
  • [Cites] Microbes Infect. 2002 Sep;4(11):1121-4 [12361911.001]
  • [Cites] Pancreas. 2003 Apr;26(3):e48-54 [12657964.001]
  • [Cites] J Histochem Cytochem. 2004 Feb;52(2):253-61 [14729877.001]
  • [Cites] Hepatology. 2004 Jan;39(1):220-9 [14752841.001]
  • [Cites] Histopathology. 1984 May;8(3):423-34 [6329942.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):806-13 [15897748.001]
  • [Cites] Prostate. 2006 Mar 1;66(4):421-9 [16302265.001]
  • [Cites] Dig Dis Sci. 2006 Feb;51(2):381-9 [16534686.001]
  • [Cites] J Dermatol. 2006 May;33(5):309-18 [16700662.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4257-64 [16857800.001]
  • [Cites] Mod Pathol. 2006 Oct;19(10):1386-94 [16880776.001]
  • [Cites] Lung Cancer. 2007 Feb;55(2):195-203 [17126950.001]
  • [Cites] Arch Pathol Lab Med. 2007 Apr;131(4):556-62 [17425384.001]
  • [Cites] Mol Cancer Res. 2007 Apr;5(4):309-20 [17406026.001]
  • [Cites] FASEB J. 2008 Apr;22(4):966-81 [18024835.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2065-70 [18381409.001]
  • [Cites] Br J Cancer. 2008 May 6;98(9):1540-7 [18392050.001]
  • [Cites] Br J Cancer. 2008 Aug 5;99(3):520-6 [18665193.001]
  • [Cites] Br J Cancer. 2008 Sep 16;99(6):949-56 [18781152.001]
  • [Cites] J Biosci. 2009 Mar;34(1):113-23 [19430123.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2000 Jan;41(1):82-8 [10634605.001]
  • (PMID = 20591909.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078590-13; United States / NCI NIH HHS / CA / U01 CA111294; United States / NCI NIH HHS / CA / R01 CA78590; United States / NCI NIH HHS / CA / P50 CA127297; United States / NCI NIH HHS / CA / R01 CA078590; United States / NCI NIH HHS / CA / R01 CA131944; United States / NCI NIH HHS / CA / R01 CA 133774; United States / NCI NIH HHS / CA / R01 CA133774
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC4 protein, human; 0 / Mucin-4; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS224552; NLM/ PMC2920126
  •  go-up   go-down


100. McHugh JB, Hoschar AP, Dvorakova M, Parwani AV, Barnes EL, Seethala RR: p63 immunohistochemistry differentiates salivary gland oncocytoma and oncocytic carcinoma from metastatic renal cell carcinoma. Head Neck Pathol; 2007 Dec;1(2):123-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 immunohistochemistry differentiates salivary gland oncocytoma and oncocytic carcinoma from metastatic renal cell carcinoma.
  • Metastatic renal cell carcinoma (RCC) can pose diagnostic challenges in the head and neck often resembling benign and malignant oncocytic lesions.
  • Morphologic features evaluated were cytoplasmic character (clear versus oncocytic), Fuhrman nuclear grade, mitotic rate, growth pattern, presence of lumens/blood lakes and stromal characteristics.
  • Tumors were stained with antibodies to p63, renal cell carcinoma marker (RCCm), CD10, and vimentin.
  • Eight benign oncocytic tumors (29%) had clear cell features while 6 metastatic RCC (37%) had oncocytic features.
  • Mitotic rates were only significantly different between benign oncocytic tumors and metastatic RCC.
  • Seven benign oncocytic tumors (25%) and 5 oncocytic carcinomas (56%) had RCC-like vascular stroma.
  • All primary salivary gland tumors were positive for p63, predominately in basal cell-type distribution.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenoma, Oxyphilic / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Membrane Proteins / metabolism. Salivary Gland Neoplasms / diagnosis. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Predictive Value of Tests

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 1999 Dec;113(6):1099-105 [10594758.001]
  • [Cites] Otolaryngol Head Neck Surg. 2002 Jun;126(6):657-62 [12087334.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • [Cites] Adv Anat Pathol. 2002 Sep;9(5):280-9 [12195217.001]
  • [Cites] Laryngoscope. 2002 Sep;112(9):1598-602 [12352670.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):428-36 [12447671.001]
  • [Cites] J Histochem Cytochem. 2003 Feb;51(2):133-9 [12533521.001]
  • [Cites] J Histochem Cytochem. 2003 Aug;51(8):1097-9 [12871991.001]
  • [Cites] Lab Invest. 1970 Dec;23(6):567-80 [5530737.001]
  • [Cites] Mich Med. 1971 Jul;70(16):616-8 [5571989.001]
  • [Cites] Laryngoscope. 1973 Jun;83(6):898-905 [4711327.001]
  • [Cites] Laryngoscope. 1981 Apr;91(4):517-9 [6261053.001]
  • [Cites] South Med J. 1981 Sep;74(9):1050-2 [7280750.001]
  • [Cites] Pathol Res Pract. 1986 Dec;181(6):684-92 [3562340.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Jan;65(1):61-6 [3422397.001]
  • [Cites] Hum Pathol. 1988 Jul;19(7):862-7 [3402976.001]
  • [Cites] Head Neck. 1989 Mar-Apr;11(2):174-8 [2656583.001]
  • [Cites] Histopathology. 1990 May;16(5):487-93 [2361662.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):514-28 [2031528.001]
  • [Cites] Pathol Annu. 1992;27 Pt 1:263-304 [1736246.001]
  • [Cites] Cancer. 1996 Dec 1;78(11):2281-7 [8940996.001]
  • [Cites] Semin Diagn Pathol. 1997 Aug;14(3):203-12 [9279976.001]
  • [Cites] J Oral Pathol Med. 1998 May;27(5):225-8 [9682986.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]
  • [Cites] Am J Surg Pathol. 2007 Jan;31(1):44-57 [17197918.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):714-8 [10227294.001]
  • [Cites] Laryngoscope. 2005 Jun;115(6):1097-100 [15933529.001]
  • [Cites] Head Neck. 2005 Aug;27(8):696-702 [16021638.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Mar;122(3):464 [10699832.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116(6):823-30 [11764070.001]
  • [Cites] Trends Genet. 2002 Feb;18(2):90-5 [11818141.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):676-85 [12033955.001]
  • [Cites] Int J Surg Pathol. 2005 Oct;13(4):329-35 [16273188.001]
  • (PMID = 20614263.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins
  • [Other-IDs] NLM/ PMC2807526
  • [Keywords] NOTNLM ; Metastatic renal cell carcinoma / Oncocytic carcinoma / Oncocytoma / p63
  •  go-up   go-down






Advertisement